Document:

prtk-ex1035_509.htm

Exhibit 10.35

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

																					
	
AWARD/CONTRACT
	
1.  THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)
	
RATING
	
PAGE OF PAGES

1                3

	
2.  CONTRACT (Proc. Inst. Ident) NO. 75A50120C00001
	
3. EFFECTIVE DATE

See Block 20C
	
4.  REQUISITION/PURCHASE REQUEST/PROJECT NO.

See Schedule

	
5.  ISSUED BY          CODE
	
ASPR-BARDA
	
6.  ADMINISTERED BY (if other than item 5) CODE
	
ASPR-BARDA

	
ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201
	
ASPR-BARDA

US DEPT OF HEALTH & HUMAN SERVICES

BIOMEDICAL ADVANCED RESEARCH & DEVELOPMENT AUT

200 INDEPENDENCE AVE, S.W.

Washington DC  20201

	
7.  NAME AND ADDRESS OF CONTRACTOR

(No., street, country, State and ZIP Code)

 
	
8.  DELIVERY FOR ORIGIN       ☒ OTHER

(See below)

	
PARATEK PHARMACEUTICALS INC 15490007

Attn:  [***]

PARATEK PHARMACEUTICALS, INC.

75 PARK PLZ FL 4

BOSTON MA 021163934
	
9.  DISCOUNT FOR PROMPT PAYMENT

	
CODE  1549007
	
FACILITY CODE
	
10.  SUBMIT INVOICES

(4 copies unless otherwise specified)

TO THE ADDRESS SHOWN IN
	

	
ITEM

	
11.  SHIP TO/MARK FOR       CODE
	
HHS
	
12. PAYMENT WILL BE MADE BY       CODE
	
PSC

	
HHS

200 Independence Avenue, SW

Washington DC 20201
	
PSC

Program Support Center

7700 Wisconsin Ave

Bethesda MD 20814

	
13.  AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION

10 U.S.C. 2304 (c) (                  )   ☒ 41 U.S.C. 3304 (a)(                     )
	
14.  ACCOUNTING AND APPROPRIATION DATA

2020.1990051.25106

	
15A  ITEM NO
	
15B.  SUPPLIES/SERVICES
	
15C.  QUANTITY
	
15D. UNIT
	
153. UNIT PRICE
	
15F AMOUNT

	
 
	
Continued
	
 
	
 
	
 
	
 

	
15G.  TOTAL AMOUNT OF CONTRACT
	

	
$59,380,559.00

	
16.  TABLE OF CONTENTS

	
☒
	
SEC.
	
DESCRIPTION
	
PAGE(S)
	
☒
	
SEC.
	
DESCRIPTION
	
PAGE(S)

	
PART I – THE SCHEDULE
	
PART II – CONTRACT CLAUSES

	
 
	
A
	
SOLICITATION/CONTRACT FORM
	
 
	
☒
	
I
	
CONTRACT CLAUSES
	
38
		
	
☒
	
B
	
SUPPLIES OR SERVICES AND PRICES/COSTS
	
3
	
PART III – LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH
	
	
☒
	
C
	
DESCRIPTION/SPECS/WORK STATEMENT
	
10
	
☒
	
J
	
list of attachments
	
42
			
	
☒
	
D
	
PACKAGING AND MARKING
	
12
	
PART IV – REPRESENTATIONS AND INSTRUCTIONS
	
	
☒
	
E
	
INSPECTION AND ACCEPTANCE
	
13
	
☒
	
K
	
REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS
	
43
			
	
☒
	
F
	
DELIVERIES OR PERFORMANCE
	
14
	
 
	
	
☒
	
G
	
CONTRACT ADMINISTRATION DATA
	
21
	
 
	
L
	
INSTRS. CONDS, AND NOTICES TO OFFERORS
	
 
	
	
☒
	
H
	
SPECIAL CONTRACT REQUIREMENTS
	
25
	
 
	
M
	
EVALUATION FACTORS FOR AWARD
	
 
	
	
CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED-BID OR NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE

 

 

 

 

				
	
17. ☒ CONTRACTOR’S NEGOTIATED AGREEMENT (Contractor is required to sign this document and return _1_ copies to issuing office.) Contractor agrees to furnish and deliver all items or perform all the services and set forth or otherwise identified above and on any continuation sheets for the consideration stated herein.  The rights and obligations of the parties to this contract shall be subject to and governed by the following documents:  (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein.  (Attachments are listed herein).
	
18. ☐ SEALED-BID AWARD (Contractor is not required to sign this document.)  Your bid on Solicitation Number 

 

including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any continuation sheets.  This award consummates the contract which consists of the following documents:  (a) the Government’s solicitation and your bid, and (b) this award/contract.  No further contractual document is necessary.  (Block 18 should be checked only when awarding a sealed-bid contract).

	
19A.  NAME AND TITLE OF SIGNER (Type or print)

[***]
	
20A.  NAME OF CONTRACTING OFFICER

[***]

 

	
19B.  NAME OF CONTRACTOR

 

By [***]

(Signature of person authorized to sign)
	
19C.  DATE 

SIGNED

 

12/18/2019
	
20B.  UNITED STATE OF AMERICA

 

By [***]

(Signature of the Contracting Officer)
	
20C.  DATE SIGNED

 

12/18/2019

 

 

 

 

 

								
	
CONTINUATION SHEET
	
REFERENCE NO. OF DOCUMENT BEING CONTINUED
	
PAGE                OF

2                         2

	
NAME OF OFFEROR OR CONTRACTOR

PARATEK PHARMACEUTICALS INC 1549007

	
ITEM NO.

(A)
	
SUPPLIES/SERVICES

(B)
	
QUANTITY

(C)
	
UNIT

(D)
	
UNIT PRICE

(E)
	
AMOUNT

(F)

	
 
	
Tax ID Number:        33-0960223
DUNS Number:        [***]
Appr. Yr.: 2020 CAN: [***] Object Class: [***]
Period of Performance: 12/18/2019 to 12/17/2024
	
 
	
 
	
 
	
[***]

	
1
	
Late Stage Development to Support Licensure of Antibiotic through EUA or FDA Marketing Authorization
Requisition No: [***]
	
 
	
 
	
 
	
[***]

	
2
	
Initial Purchase, Storage, and Delivery of Antibiotic as FDP to VMI or SNS Obligated Amount: [***]
Requisition No: [***]
	
 
	
 
	
 
	
0.00

	
3
	
Supplemental Late Stage Development as Requested by FDA to Support Licensure of Antibiotics through FDA Marketing Authorization 
Amount: $12,672,339.00(Option Line Item)
	
 
	
 
	
 
	
0.00

	
4
	
BARDA Security Requirements
Amount: $20,435,260.00(Option Line Item)
	
 
	
 
	
 
	
0.00

	
5
	
Post-Marketing Study Commitments/Requirements for Authorized Commercial Indication including Relabeling of Approved Drug in the ASPR/SNS or VMI
Amount: $76,774,872.00(Option Line Item)
	
 
	
 
	
 
	
0.00

	
6
	
Additional Procurement of Antibiotics as Final Drug Product ([***])
Amount: [***] (Option Line Item)
	
 
	
 
	
 
	
0.00

	
7
	
Additional Procurement of Antibiotics as Final Drug Product ([***])
Amount: [***] (Option Line Item)
	
 
	
 
	
 
	
0.00

	
8
	
Additional Procurement of Antibiotics as Final Drug Product ([***])
Amount: [***] (Option Line Item)
	
 
	
 
	
 
	
0.00

 

 

 

 

 PART I – THE SCHEDULE

SECTION B – SUPPLIES OR SERVICE AND PRICE / COST

ARTICLE B.1.  BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

Paratek is developing NUZYRA® (omadacycline), an oral and parenteral antibiotic to treat pulmonary anthrax. The drug product is also suitable for prophylactic use as a priority medical countermeasure.

Under the base period-of-performance, Paratek will conduct development activities necessary to achieve an Emergency Use Authorization (EUA) licensure of NUZYRA® followed by the supplemental NDA submission and drug product manufacturing of the drug product to be stored as vendor managed inventory (VMI) and subsequently delivered to the Strategic National Stockpile (SNS). The contract options may be exercised to perform additional studies necessary for licensure, support post-licensure commitments as required by the FDA, implement additional security requirements and procure additional treatment courses.

The Research and Development (R&D) effort will progress in specific stages that cover the base performance segment and several options, if necessary, as specified in this contract. The period of performance for the base period is 60 months.

ARTICLE B.2.  BASE PERIOD

 

	
Base Period Cost Reimbursement CLIN

	
CLIN
	
Period of

Performance
	
Supplies/Services
	
Estimated

Cost
	
Fixed Fee
	
Cost + Fixed

Fee (CPFF)

	
0001 

(Base)
	
[***]
	
Late stage development activities towards FDA approval for treatment of pulmonary Anthrax
	
[***]
	
[***]
	
[***]

 

	
Base Period Fixed Price CLINs

	
CLIN
	
Period of

Performance
	
Supplies/Services
	
Treatment

Courses

(# of Product)
	
Unit Price

($)
	
Total

($)

	
0002 

(Base)
	
[***]
	
Initial purchase and delivery of NUZYRA® via VMI
	
2,500
	
[***]
	
[***]

 

*Total funded to date is $59,380,559

3

 

ARTICLE B.3.  OPTIONS

 

	
Optional Cost Reimbursement CLINs

	
CLIN
	
Period of 

Performance
	
Supplies/ Services
	
Total Est. 
Cost
	
Fixed Fee
	
Total Cost Plus Fixed Fee ($)

	
0003

(Option)
	
[***]
	
Supplemental Late stage development as requested by FDA to support licensure of antibiotic(s) through FDA marketing authorization (nonclinical, clinical, regulatory)
	
[***]
	
[***]
	
$12,672,339

	
0004

(Option)
	
06/01/2020 – 

[***]
	
BARDA Security Requirements
	
[***]
	
[***]
	
$20,435,260

	
0005

(Option)
	
04/01/2020 – 

[***]
	
Post-Marketing Study Commitments/ Requirements for the authorized commercial indication including relabeling of approved drug in the ASPR/SNS or VMI (this is an option that may or may not be exercised as required by the FDA)
	
[***]
	
[***]
	
$76,774,872

4

 

 

 

	
Optional Fixed Price CLINs

	
CLIN
	
Period of

Performance
	
Supplies/Services
	
Treatment

Courses

(# of Product)
	
Unit Price

(SNS/VMI)
	
Total

($)

	
0006

(Option)
	
[***]
	
Additional procurement of antibiotic(s) as final drug product (FDP) to Vendor managed inventory (VMI) and/or ASPR/SNS sites.
	
[***]
	
[***]
	
[***]

	
0007

(Option)
	
[***]
	
Additional procurement of antibiotic(s) as final drug product (FDP) to Vendor managed inventory (VMI) and/or ASPR/SNS sites.
	
[***]
	
[***]
	
[***]

	
0008

(Option)
	
[***]
	
Additional procurement of antibiotic(s) as final drug product (FDP) to Vendor managed inventory (VMI) and/or ASPR/SNS sites.
	
[***]
	
[***]
	
[***]

 

ARTICLE B.4.  ADVANCE UNDERSTANDINGS

	
 
	
a.
	
Subcontracts and Consultants

Award of any FFP subcontract or FFP consulting agreement in excess of $250,000 or any cost reimbursement subcontract or consulting agreement shall not proceed without the prior written consent of the Contracting Officer via a Contracting Officer Authorization (COA) Letter. COA letters will only be issued upon review of the supporting documentation required by FAR Clause 52.244-2, Subcontracts. After receiving written consent of the subcontract by the Contracting Officer, a copy of the signed, executed subcontract and consulting agreement shall be provided to the Contracting Officer within ten (10) calendar days of full execution.

5

 

 

	
 
	
b.
	
Site Visits, Inspections and General Audits

At the discretion of the USG and independent of activities conducted by the Contractor, with 48 hours’ notice to the Contractor, the USG reserves the right to conduct site visits and inspections on an as needed basis in connection with technical performance issues, including collection of product samples and intermediates held by the Contractor, or subcontractor. In case of subcontractor visits and inspections related to performance under this contract that are independent of activities conducted by the Contractor, the USG shall demonstrate cause for such visit and/or inspection. All costs reasonably incurred by the Contractor and subcontractor for such visit and/or inspection shall be allowable costs. The Contractor shall coordinate these visits and shall have the opportunity to accompany the USG on any such visits. Under time-sensitive or critical situations, the USG reserves the right to suspend the 48 hour notice to the Contractor. If the Government, Contractor, or other party identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and provide a report to the Government for review and acceptance.

	
 
	
•
	
If issues are identified during the audit, Contractor shall submit an issue report to the CO and COR within 10 business days detailing the finding and corrective action(s) of the audit.

	
 
	
•
	
COR and CO will review the issues report and provide a response to the Contractor within 10 business days.

	
 
	
•
	
Once corrective action is completed, the Contractor will provide a final report to the CO and COR within a time frame negotiated with the COR in writing after review of the issues report.

	
 
	
c.
	
QA Audits

BARDA reserves the right to participate in QA audits of the Contractor’s subcontractors to the extent related to performance of this contract. Upon completion of the QA audit the Contractor shall provide a report capturing the findings, results, and next steps in proceeding with any potential subcontractors. If action is requested for a subcontractor, detailed corrective and preventative plans for addressing areas of non-conformance to ICH and FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to the COR for review and acceptance. The Contractor shall provide responses from the subcontractors to address these concerns and plans for corrective action execution.

	
 
	
•
	
Contractor shall notify CO and COR of upcoming, ongoing, or recent audits/site visits of subcontractors by the Contractor as part of bi-weekly communications;

	
 
	
•
	
Contractor shall notify the COR and CO within 10 business days of report completion. The Contractor shall complete the report within 60 days of the audit/site visit, or as negotiated with the COR in writing dependent upon the audit findings;

	
 
	
•
	
COR and CO will review the issues report and provide a response to the Contractor within 10 business days;

6

 

 

	
 
	
•
	
Once corrective action is completed, the Contractor will provide a final report to the CO and COR within a time frame negotiated with the COR and CO after review of the issues report.

	
 
	
•
	
If additional details are needed for clarification of role, responsibility and processes between the Contractor and USG, it will be defined in the Quality Agreement outlined in Article B.5, Section h, below.

	
 
	
d.
	
Man-in-Plant

At the discretion of the Government and seven calendar (7) days advance notice to the Contractor in writing from the Contracting Officer, the Government may place a man-in-plant in the Contractor’s facility, who shall be subject to the Contractor’s policies and procedures regarding security and facility access at all times while in the Contractor’s facility. Consistent with federal law, the Government will ensure that no Government representative will publish, divulge, disclose, or make known in any manner, to any extent not authorized by law, any information coming to him in the course of employment or official duties, while stationed in a contractor plant.

	
 
	
e.
	
Sharing of contract deliverables within United States Government (USG)

In an effort to build a robust medical countermeasure pipeline through increased collaboration, BARDA may share technical deliverables with USG entities responsible for Medical Countermeasure Development. In accordance with recommendations from the Public Health Emergency Medical Countermeasure Enterprise Review, agreements established in the Integrated Portfolio’s Portfolio Advisory Committee (PAC) Charter, and agreements between BARDA and the Department of Defense and the National Institutes of Health, BARDA may share technical deliverables and data created in the performance of this contract with colleagues within the Integrated Portfolio. This advance understanding does not authorize BARDA to share financial information outside HHS. The Contractor is advised to review the terms of FAR 52.227-14, Rights in Data – General, regarding the Government’s rights to deliverables submitted during performance as well as the Government’s rights to data contained within those deliverables.

	
 
	
f.
	
Overtime Compensation

No overtime (premium) compensation is authorized under the subject contract.

	
 
	
g.
	
Contract Number Designation

On all correspondence submitted under this contract, the Contractor agrees to clearly identify the contract number that appears on the face page of the contract as follows:

75A50120C00001

	
 
	
h.
	
Quality Agreement

The Quality Agreement shall define, establish, and document the responsibilities of both the Contractor and the USG (i.e. – CDC/SNS-Quality Control and BARDA) for event-

7

 

 

driven and product shipping, receiving, acceptance into the inventory and/or custody by the USG. These documents shall be drafted, approved, and signed by all parties prior to the commencement of product procurement and acceptance, transport and custody of the product under the VMI/DMI or the CDC/SNS. The Contractor shall provide documentation and resolution for all concerns raised by USG and commits to cooperation in execution of this agreement. A COA will be required prior to invoicing against procurement CLINs.

	
 
	
i.
	
Liquidated Damages

If the Contractor fails to deliver the supplies or perform the services within the time specified and agreed upon by both parties in this contract, and such failure is not excusable or remedied within 14 calendar days. Beyond this time frame the Contractor shall, in place of damages, pay the Government liquidated damages an amount per calendar day of delay to be agreed upon prior to the execution of FFP optional procurement CLINs.

	
 
	
j.
	
[***]

	
 
	
k.
	
[***]

	
 
	
l.
	
[***]

	
 
	
m.
	
[***]

	
 
	
n.
	
[***]

 

 

8

 

 

ARTICLE B.5.  PROVISIONS TO APPLICABLE COSTS

This section prohibits or restricts the use of contract funds to reimburse direct cost expenditures for the following items (costs unallowable unless otherwise approved by the Contracting Officer):

	
 
	
a)
	
Acquisition, by purchase or lease, of any interest in real property;

	
 
	
b)
	
Rearrangement or alteration of facilities;

	
 
	
c)
	
Purchase of lease of any item of general purpose office furniture or office equipment regardless of dollar value;

	
 
	
d)
	
Accountable Government Property;

	
 
	
e)
	
Overtime

	
 
	
f)
	
General scientific meetings/conferences;

	
 
	
g)
	
Travel costs including foreign travel;

	
 
	
h)
	
Costs incurred in the performance of any cost-reimbursement type subcontract (including consulting agreements);

	
 
	
i)
	
Costs to be paid for the performance of a fixed-price subcontract that exceeds $150,000.00;

	
 
	
j)
	
Refreshments and Meal Expenditures;

	
 
	
k)
	
Promotional Items

	
 
	
l)
	
Printing

 

 

9

 

SECTION C – DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

ARTICLE C.1.  STATEMENT OF WORK

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Statement of Work dated December 18, 2019 set forth in SECTION J - List of Attachments, attached hereto and made a part of the contract.

ARTICLE C.2.  REPORTING REQUIREMENTS

See Section F for specific reporting requirements.

All reports required herein shall be submitted in electronic format. All paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double-sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b).

ARTICLE C.3.  MEETINGS/SITE VISITS

The Contractor and BARDA shall participate in regular meetings to coordinate and oversee the contracting effort as requested by the Contracting Officer (CO)/Contracting Officer’s Representative (COR). Such meetings may include, but are not limited to, a kickoff meeting to be held at a location determined by the COR, status update meetings and/or teleconferences, site visits to the Contractor’s and/or subcontractor’s facilities, and meetings with individual Contractors and other HHS officials to discuss the technical, regulatory, and ethical aspects of the program. The Contractor shall provide data, reports, and presentations to groups of outside experts and USG personnel and USG-contracted subject matter experts as required by the CO/COR facilitating review of activities.

The purpose of the kickoff meeting will be to orient the Contractor to HHS/BARDA and review contract requirements. This meeting usually occurs within a month after contract award.

Bi-weekly (i.e. – every two weeks) or monthly status update meetings/teleconferences shall be scheduled and established by the Contracting Officer’s Representative (COR), the Contractor’s Project Leaders/delegates and Contracting Officer (CO). During this meeting the Contractor’s Project Leaders/delegates and designees will discuss the activities since the last call, any problems that have arisen and the activities planned until the next call takes place. The Contractor’s Project Leaders/delegates may choose to include other key personnel on the conference call to give detailed updates on specific projects or this may be requested by the Contracting Officer’s Representative.

Within five (5) calendar days of Paratek’s receipt of the audit report of an FDA audit of Contractor or subcontractor facilities related to activities performed under this contract, the Contractor shall provide copies of the audit findings, final report, and a plan for addressing areas of nonconformance to FDA regulations and guidance for GLP, GMP or GCP guidelines as identified in the final audit report.

10

 

Other U.S. Government Audits

The USG reserves the right to conduct an audit of the Contractor with 72 hours advance notice in connection with technical performance issues. The USG reserves the right to accompany the Contractor on routine and for-cause site-visits/audits of subcontractor(s) related to work performed under this contract. At the discretion of the USG and independent of testing conducted by the Contractor, BARDA reserves the right to conduct site visits/audits and collect samples of product held produced under this contract and held by the Contractor and subcontractors.

Pre-award site visits may be made with short notice. Contractors are expected to guarantee the availability of key staff or other staff determined by the Government as essential for purposes of this site visit.

 

 

11

 

 

SECTION D – PACKAGING, MARKING AND SHIPPING

ARTICLE D.1.  METHOD OF DELIVERY

Unless otherwise specified by the Contracting Officer, all deliverable items to be furnished to the Government under this contract (including invoices) shall be made by first class mail, overnight carrier, or email as described in SECTION F.3.

All deliverables required under this contract shall be packaged, marked and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked with the contract number and Contractor’s name. The Contractor shall guarantee that all required materials shall be delivered in immediate usable and acceptable condition.

ARTICLE D.2.  FOB DESTINATION DELIVERIES

The Contractor shall describe the storage conditions for each product, specifically noting the acceptable temperature range required to maintain product quality. The Contractor shall be responsible for maintaining product temperature control until the product(s) arrives at the ASPR/SNS and has completed product acceptance by the USG. The Contractor shall provide the Government with an ambient exposure letter that covers the time the product(s) leaves the Contractor’s validated storage facility until arrival at the ASPR/SNS. Upon Government acceptance of the product(s) to the Government, the responsibility for temperature control shall transfer to the Government as well as the responsibility for logging ambient exposure time (temperatures between 8-25°C). The Contractor will provide and place TempTale(s) on each pallet of product while the product is inside the Contractor’s validated storage facility prior to placing the product(s) onto the truck(s) or other mode of transportation of the designated carrier. The Government’s acceptance of the aforementioned responsibility applies only to temperature control and does not indicate its acceptance of the lot(s).

 

 

12

 

SECTION E – INSPECTION AND ACCEPTANCE

ARTICLE E.1.  INSPECTION AND ACCEPTANCE

Inspection and acceptance of reports will be performed by the Contracting Officer or a duly authorized representative. Technical inspection and acceptance for reports will take place at:

Biomedical Advanced Research and Development Authority

Office of the Assistant Secretary for Preparedness and Response

200 C Street, S.W.

Washington, D.C. 20024

Inspection or acceptance of product will take place at the VMI or SNS location.

Acceptance may be presumed unless otherwise indicated in writing by the Contracting Officer or the duty authorized representative within 30 days of receipt.

ARTICLE E.2.  FEDERAL ACQUISITION REGULATION CLAUSES INCORPORATED BY REFERENCE

This contract incorporates the following clause by reference, with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text available.

FAR 52.246-2, Inspection of Supplies – Fixed Price (August 1996)

FAR 52.246-4, Inspection of Services - Fixed Price (August 1996)

FAR 52.246-5, Inspection of Services - Cost-Reimbursement (April 1984)

FAR 52.246-8, Inspection of Research and Development – Cost-Reimbursement (May 2001)

FAR 52.246-9, Inspection of Research and Development (Short Form) (April 1984)

FAR 52.246-16, Responsibility for Supplies (April 1984)

 

13

 

 

SECTION F -- DELIVERIES OR PERFORMANCE

ARTICLE F.1.  PERIOD OF PERFORMANCE

The base period of performance of this contract shall be for sixty (60) months from the date of award. The period of performance may be extended up to an additional 5 years (10 years total for base plus options) with the exercise of option(s), structured as CLINs, as set forth in SECTION B. The period of performance for the base period and option periods shall be consistent with the dates set forth in SECTION B.

ARTICLE F.2.  Reporting Requirements

The Contractor shall submit to the CO and the COR technical progress reports as identified below. These reports shall be subject to the technical inspection and requests for clarification by the COR, and approval by the CO/COR. These reports shall be brief, factual, and prepared in accordance with the following format:

	
 
	
a.
	
Monthly Progress Report

This report shall include a description of the activities during the reporting period and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist of each calendar month.

The Contractor shall submit a Monthly Progress Report on or before the 15th calendar day following the last day of each reporting period and shall include the following:

Title Page: The title page for this report shall include the contract number and title; the type of  report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail address; and the date of submission.

Distribution List: A list of individuals receiving the Technical Progress report.

Progress:

SECTION I - An introduction covering the purpose and scope of the contract effort.

SECTION II Part A: SUMMARY - A description or table summarizing ongoing activities.

SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE – This section shall include a description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g. evaluating and managing subcontractor performance and personnel changes). Please include all Quality Management System, Quality Control, and Quality Assurance Plans as part of this report or as requested by the COR.

14

 

SECTION II Part C: TECHNICAL PROGRESS – This section shall document the results of work completed and costs incurred during the period covered in relation to the proposed progress, effort, and budget. The report shall be in sufficient detail to explain comprehensively the results achieved.

SECTION II Part D: ISSUES – This section shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress; why the differences have occurred and what corrective actions are planned; and if a project activity is delinquent, then what corrective action steps are planned. Revised timelines shall be provided.

SECTION II Part E: PROPOSED WORK – This section shall include a summary of work proposed as a rolling three (3) month forecast for the next reporting period, by a certain date, and by whom.

SECTION II Part F: MANUFACTURING AND SUPPLY CHAIN MANAGEMENT – This section shall include a summary of the manufacturing and supply-chain related activities. Also include in this section updates to the production plan, capacity projections, stability results, inventory and shipment/distribution information.

SECTION II Part G: CONTRACTING OFFICER APPROVALS – This section shall include a table indicating each Contracting Officer Approval (COA) request, its current status (e.g. date submitted, date approved, date returned), amount requested, and the vendor for which the COA authorizes subcontracted work to be performed.

Invoices: Summary of any invoices submitted during the reporting period.

A Monthly Progress Report will not be required in the same month Annual Progress Reports or a Final Report are due.

	
 
	
b.
	
Annual Progress Report

This report shall include a summation of the activities during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full year of performance plus any fractional part of the initial year. Thereafter, the reporting period shall consist of each calendar year.

The Contractor shall submit an Annual Progress Report on or before the 30th calendar day following the last day of each annual reporting period and shall include the following:

Title Page: The title page for this report shall include the contract number and title; the type of  report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail address; and the date of submission.

Distribution List: A list of individuals receiving the Technical Progress report.

Progress:

15

 

 

SECTION I - An introduction covering the purpose and scope of the contract effort.

SECTION II Part A: SUMMARY - A description or table summarizing ongoing activities.

SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE – This section shall include a description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g. evaluating and managing subcontractor performance and personnel changes). Please include all Quality Management System, Quality Control, and Quality Assurance Plans as part of this report or as requested by the COR.

SECTION II Part C: TECHNICAL PROGRESS – This section shall document the results of work completed and costs incurred during the period covered in relation to proposed progress, effort, and budget. The report shall be in sufficient detail to explain comprehensively the results achieved.

SECTION II Part D: ISSUES – This section shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress; why the differences have occurred and what corrective actions are planned; and if a project activity is delinquent, then what corrective action steps are planned. Revised timelines shall be provided.

SECTION II Part E: PROPOSED WORK – This section shall include a summary of work proposed as a rolling three (3) month forecast for the next reporting period, by a certain date, and by whom.

SECTION II Part F: MANUFACTURING AND SUPPLY CHAIN MANAGEMENT – This section shall include a summary of the manufacturing and supply-chain related activities. Also include in this section updates to the production plan, capacity projections, stability results, inventory and shipment/distribution information.

SECTION II Part G: CONTRACTING OFFICER APPROVALS – This section shall include a table indicating each Contracting Officer Approval (COA) request, its current status (e.g. date submitted, date approved, date returned), amount requested, and the vendor for which the COA authorizes subcontracted work to be performed.

Invoices: Summary of any invoices submitted during the reporting period.

An Annual Progress Report will not be required for the period when the Final Technical Progress Report is due.

	
 
	
c.
	
Draft Final Report and Final Report

These reports are to include a summation of the work performed and results obtained for execution of various studies or technical work packages during the entire contract period of performance. This report shall be in sufficient detail to describe comprehensively the results achieved. The Draft Final Progress Report shall be due forty-five (45) calendar 

16

 

 

days prior to the expiration date of the contract and the Final Progress Report is due no later than 30 days following the expiration date of the contract. The report shall conform to the following format:

Title Page: The title for these reports shall include the contract number and title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e- mail address; and the date of submission.

Distribution List: A list of individuals receiving the Technical Progress report.

Progress:

SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work.

SECTION II: RESULTS - A detailed description of the work performed and the results obtained including all expenses for the entire contract period of performance.

	
 
	
d.
	
FDA Regulatory Agency Correspondence, Meeting Summaries, and Submissions.

	
 
	
a)
	
Within five business days of any formal meeting with the FDA or other regulatory agency that relates to performance of this contract, the Offeror shall forward the initial draft minutes to the COR. The Offeror shall forward the final minutes when available.

	
 
	
b)
	
If related to performance of this contract, the Contractor shall forward the dates and times of any meeting with the FDA and other regulatory agencies to the COR as soon as the meeting times are known and make arrangements for appropriate BARDA staff to attend the meetings.

	
 
	
c)
	
If related to performance of this contract, the Contractor shall provide the COR the opportunity to review and comment upon any documents to be submitted to the FDA or other regulatory agency. The Contractor shall provide the COR with five (5) business days in which to review and provide comments back to the Contractor prior to the Contractor’s submission to the FDA.

	
 
	
d)
	
The Contractor shall forward Standard Operating Procedures (SOPs) upon request from the COR.

	
 
	
e)
	
The Contractor shall provide raw data and/or specific analysis of data generated with USG funds upon request from the COR.

	
 
	
f)
	
If related to performance of this contract, the Contractor shall notify the Contracting Officer’s Representative and Contracting Officer within 24 hours of all FDA arrivals to conduct site visits/audits by any regulatory agency. The Contractor shall provide the USG with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR) to the extent related to performance of this 

17

 

 

	
 
		
contract. The Offeror shall provide the Contracting Officer’s Representative and Contracting Officer copies of the plan for addressing areas of non-conformance to FDA regulations for GLP guidelines as identified in the audit report, status updates during the plans execution, and a copy of all final responses to the FDA to the extent related to performance of this contract. The Contractor shall also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or for this product. The redactions shall be limited to issues that are unrelated to the subcontractor’s performance on any award made under this RFP. The Contractor shall make arrangements with the COR for the appropriate BARDA representative(s) to be present during the final debrief by the regulatory inspector.

	
 
	
e.
	
Other Requirements/Deliverables

	
 
	
a)
	
Integrated Master Project Plan

The Contractor shall provide an Integrated Master Project Plan (including tabular and Gantt forms) to the COR that clearly indicates the critical path to annual deliverables and Work Breakdown Structure (WBS) elements. Attention shall be placed on providing sufficient turnaround time for the USG (BARDA, FDA, and CDC) for review of critical documentation. The Contractor shall integrate to demonstrate interdependencies among all CLINS. The Integrated Master Project Plan shall be incorporated into any potential contract and will be used to monitor performance of the contract. This report shall be due within 90 days of contract award. Updates shall be due as requested by the COR.

	
 
	
I.
	
Critical Path Milestones

The Integrated Master Project Plan shall outline key, critical path milestones, with “Go/No Go” decision criteria (entrance and exit criteria for each phase of the project). This report shall be due within 90 days of contract award. Updates shall be due as requested by the COR.

	
 
	
II.
	
Work Breakdown Structure

The WBS shall be discernable and consistent. The COR may require the Contractor to furnish WBS data at the work package level or at a lower level if there is significant complexity and risk associated with the task. This report shall be due within 90 days of contract award. Updates shall be due as requested by the COR.

	
 
	
III.
	
Risk Mitigation Plan/Matrix

The Contractor shall develop and maintain a risk management plan that highlights potential problems and/or issues that may arise during the life of the contract, their impact on cost, schedule and performance, and appropriate remediation plans. This plan shall reference relevant WBS/SOW elements where appropriate. The USG has provided a Risk Mitigation Matrix template (See http://www.phe.gov/about/amcg/contracts/Pages/toolkit.aspx) to be completed 

18

 

 

by any prospective Contractor. This report shall be due within 90 days of contract award. Updates shall be due as requested by the COR.

	
 
	
1.
	
Technology Packages

Technology packages developed under the contract that includes complete protocols must be submitted at the request of the Contracting Officer’s Representative. See FAR clauses 52.227-11, Patent Rights-Ownership by the Contractor, and 52.227-14, Rights in Data, Alternate II. This report shall be due upon request from the COR.

	
 
	
2.
	
Experimental Protocols

The Contractor shall submit to the COR all study/experiment/test plans, designs, and protocols prior to execution for approval or upon request by the COR when required.

	
 
	
3.
	
Annual/Final Invention Report

All reports and documentation required by FAR Clause 52.227-11, Patent Rights- Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support certification. An Annual Invention Report shall be due on or before the 30th calendar day after the completion of each reporting period. A Final Invention Report (see FAR 27.303 (b)(2)(ii)) shall be due on or before the expiration date of the contract. If no invention is disclosed or no activity has occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to the Contracting Officer.

	
 
	
4.
	
Publications

Any manuscript or scientific meeting abstract containing data generated under this contract must be submitted to COR for review prior to submission. Reports shall be due within 30 calendar days for manuscripts and 15 calendar days for abstracts.

	
 
	
5.
	
Press Releases

The Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases. The Contractor shall ensure the Contracting Officer has received and approved an advanced copy of any press release not less than five (5) business days prior to the issuance of any potential press release.

	
 
	
6.
	
Security Report

To the extent related to performance of this contract, the Contractor shall report to the government any activity; or incident that is in violation of 

19

 

 

established security standards; or indication of loss or theft of government products. Reports shall be due within 24 hours after occurrence of an activity or incident.

	
 
	
7.
	
Security Plan

Final plan due within 90 days of contract award.

	
 
	
8.
	
Quality Management System Plan

The Contractor shall submit to the COR a Quality Management System Plan for approval no later than 90 days from the date of award.

	
 
	
9.
	
Manufacturing Plan

The Contractor shall submit to the COR a comprehensive manufacturing plan for review and approval no later than 90 days from the date of award.

ARTICLE F.3.  DELIVERABLE SCHEDULE

 

	
Item

No.
	
Description
	
Addresses
	
Deliverable Schedule

	
1
	
Monthly Progress Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Reports are due on or before the 15th of each month following the end of each reporting period.

	
2
	
Annual Progress Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Reports are due on or before the 30th calendar day following the end of each reporting period.

	
3
	
Draft Final Progress Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Report is due 45 Calendar days prior to the expiration date of the contract.

	
4
	
Final Progress Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Report is due no later than 30 calendar days after the expiration date of the contract.

	
5
	
FDA/ Regulatory Agency Correspondence and Meeting Summaries
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Meeting summaries/minutes are due within 5 business days of receipt from the FDA/regulatory agency, or upon request from the COR.

20

 

 

	
Item

No.
	
Description
	
Addresses
	
Deliverable Schedule

	
6
	
Integrated Master Project Plan

-Critical Path Milestones

-Work Breakdown Structure

-Risk Mitigation Plan/Matrix
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Report is due within 90 days of contract award. Updates are due as requested by the COR.

	
7
	
Technology Packages
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Upon request from the COR.

	
8
	
Experimental Protocols
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Upon request from the COR.

	
9
	
Annual/Final Invention Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
An Annual Invention Report is due on or before the 30th calendar day after the completion of each annual reporting period. A Final Invention Report is due on or before the expiration date of the contract.

	
10
	
Publications
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Reports are due within 30 calendar days for manuscripts and 15 calendar days for abstracts.

	
11
	
Press Releases
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Reports/Notices are due for review by the CO not less than five (5) business days prior to the issuance of any potential press release.

	
12
	
Security Report
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Reports are due within 24 hours after occurrence of an activity or incident.

	
13
	
Security Plan
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Final plan due within 90 days of contract award.

	
14
	
Manufacturing Plan
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Due within 90 days of contract award.

	
15
	
Quality Management System Plan
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Due within 90 days of contract award

	
16
	
Delivery Schedule to the ASPR/SNS or product maintained as VMI
	
CO: (1) electronic copy

 

COR: (1) electronic copy
	
Due within 30 days of agreement on delivery location.

21

 

 

 

ARTICLE F.4.  FEDERAL ACQUISITION REGULATION CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

This contract incorporates the following clause(s) by reference, with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text available. The full text of each clause may be accessed electronically at this address: http://www.acquisition.gov/comp/far/index.html.

FAR 52.242-15, Stop-Work Order (August 1989)

FAR 52.242-15, Stop-Work Order, Alternate 1 (April 1984)

 

 

22

 

 

SECTION G– CONTRACT ADMINISTRATION

ARTICLE G.1.  CONTRACTING OFFICER (CO)

The following Contracting Officer (CO) will represent the Government for the purpose of this contract: 

[***]

DHHS/OS/ASPR/BARDA

200 C St.

O’Neill House Office Building 

Washington, D.C. 20515

The Contracting Officer is the only individual who can legally commit and bind the Government to the expenditure of public funds. No person other than the Contracting Officer can make any changes to the terms, conditions, general provisions or other stipulations of this contract. Any other commitment, either explicit or implied, is invalid.

The CO is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the statement of objectives; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; (5) obligate or de-obligate funds into the contract; (6) sign written licensing agreements; or (7) otherwise change any terms and conditions of this contract.

No information, other than that which may be contained in an authorized modification to this contract duly issued by the Contracting Officer, which may be received from any person employed by the United States Government, or otherwise, shall be considered grounds for deviation from any stipulation of this contract.

The Government may unilaterally change its CO designation.

ARTICLE G.2.  CONTRACTING OFFICER’S REPRESENTATIVE (COR)

The following Contracting Officer’s Representative (COR) will represent the Government for the purpose of this contract:

[***]

Contracting Officer’s Representative

Biomedical Advanced Research and Development Authority (BARDA)

Office of the Assistant Secretary for Preparedness and Response

Department of Health and Human Services

[***]

Mailing Address:

200 C St.

O’Neill House Office Building (BARDA)

Washington, D.C. 20515

23

 

The COR is responsible for:

	
 
	
a.
	
Monitoring the Contractor’s technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements;

	
 
	
b.
	
Assisting the Contracting Officer in interpreting the statement of work and any other technical performance requirements;

	
 
	
c.
	
Performing technical evaluation as required;

	
 
	
d.
	
Performing technical inspections and assisting the Contracting Officer in acceptances of deliverables required by this contract;

	
 
	
e.
	
Assisting in the resolution of technical problems encountered during performance;

	
 
	
f.
	
The Government may unilaterally change its COR designation(s).

ARTICLE G.3.  CONTRACTOR’S POINTS OF CONTACT

The Offeror shall provide primary and secondary points of contact that will be available 24 hours per day, 7 days per week, to be notified in case of a public health emergency.

ARTICLE G.4.  KEY PERSONNEL

The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) to permit evaluation by the Government of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the Contractor or Government.

The following individuals are considered to be essential to the work being performed hereunder:

 

		
	
Name
	
Title

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

24

 

 

ARTICLE G.5.  INVOICE SUBMISSION

	
 
	
a.
	
The Contractor shall submit an electronic copy of contract monthly invoices/financial reports to the Contracting Officer as defined above, in SECTION G of this contract.

	
 
	
b.
	
Contractor invoices/financial reports shall conform to the form, format, and content requirements of the instructions for Invoice/Financing requests made a part of the contract at Section J, Attachments 2 & 3.

	
 
	
c.
	
Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the Government.

	
 
	
d.
	
The Contractor agrees to immediately notify the Contracting Officer in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10 percent) of the estimated costs for the base period or any options (See estimated costs under Articles B.2 and B.3) and the reasons for the variance. Also refer to the requirements of FAR Clause 52.232-20, Limitation of Cost.

	
 
	
e.
	
The Contractor shall submit an electronic copy of the payment request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment via e-mail to the address listed below in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF). Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor’s name, contract number, and unique invoice number.

	
 
	
f.
	
All invoice submissions shall be in accordance with FAR Clause 52.232-25, Prompt Payment (Alternate I for cost-reimbursement CLINs)

	
 
	
g.
	
The Contractor may not invoice for any CLIN prior to delivery and acceptance of supplies or services except to the extent that this Contract otherwise permits the Contractor to invoice every thirty days under cost-reimbursement CLINs.

	
 
	
h.
	
Invoices shall be delivered electronically to the Contracting Officer (CO), the Contracting Officer’s Representative (COR), PSC, and e-Room electronically. Unless otherwise specified by the Contracting Officer, all deliverables, invoices, and reports furnished to the Government under the resultant contract shall be addressed as follows:

 

	
[***]

 Officer HHS/ASPR/BARDA

200 C Street, S.W.

O’Neill House Office Building Washington, DC 20515

[***]
	
[***]

Contracting Officer Representative HHS/ASPR/BARDA

200 C Street, S.W.

O’Neill House Office Building Washington, DC 20515

[***]
	
[***]

 

25

 

 

ARTICLE G.6.  PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (DECEMBER 2013)

	
 
	
a.
	
Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.

	
 
	
b.
	
The acceleration of payments under this clause does not provide any new rights under the Prompt Payment Act.

	
 
	
c.
	
Include the substance of this clause; include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.

ARTICLE G.7.  CONTRACT COMMUNICATIONS/CORRESPONDENCE

The Contractor shall identify all correspondence, reports, and other data pertinent to this contract by imprinting the contract number 75A50120C00001 from Page 1 of the contract.

ARTICLE G.8.  POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

Interim and final evaluations of Contractor performance will be prepared on this contract in accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at the time of completion of work. In addition to the final evaluation, interim evaluation(s) will be prepared annually as to coincide with the Anniversary date of the contract.

Interim and final evaluations will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer whose decision will be final.

Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.

	
 
	
2.
	
Electronic Access to Contractor Performance Evaluations

Contractors may access evaluations through a secure website for review and comment at the following:

http://cpars.gov

 

26

 

 

ARTICLE G.9.  REIMBURSEMENT OF COST

The Government shall reimburse the Contractor those costs determined by the Contracting Officer to be allowable (hereinafter referred to as allowable cost) in accordance with FAR 52.216-7, Allowable Cost and Payment and FAR Subpart 31.2.

ARTICLE G.10.  GOVERNMENT PROPERTY

	
1.
	
In addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this contract, the Contractor shall comply with the provisions of HHS Publication, “Contractor’s Guide for Control of Government Property,” which is incorporated into this contract by reference. This document can be accessed at:

http://www.hhs.gov/hhsmanuals/ (HHS Logistics Management Manual)

Among other issues, this publication provides a summary of the Contractor’s responsibilities regarding purchasing authorizations and inventory and reporting requirements under the contract.

	
2.
	
Notwithstanding the provisions outlined in the HHS Publication, “Contractor’s Guide for Control of Government Property,” which is incorporated in this contract in paragraph 1. above, the Contractor shall use the form entitled, “Report of Government Owned, Contractor Held Property” for submitting summary reports required under this contract, as directed by the Contracting Officer or his/her designee. This form is included as an attachment in SECTION J of this contract.

	
3.
	
Title will vest in the Government for equipment purchased as a direct cost.

ARTICLE G.11.  INDIRECT COST RATES

The following provisional indirect rates will be utilized for billing purposes during the period of performance:

Overhead: [***]

Fringe: [***]

Final indirect rates will be established annually through an internal auditor.

 

 

27

 

 

SECTION H – SPECIAL CONTRACT REQUIREMENTS

The Contractor is responsible for following the requirements below in conducting its own work under this Contract. The Contractor also is responsible for incorporating these provisions into any subcontract awarded, if applicable to the specific nature of the work in the subcontract. Accordingly, those provisions shall be flowed-down as applicable.

ARTICLE H.1.  PROTECTION OF HUMAN SUBJECTS

	
 
	
a.
	
The Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall be protected in accordance with 45 CFR Part 46 and with the Contractor’s current Assurance of Compliance on file with the Office for Human Research Protections (OHRP), Department of Health and Human Services. The Contractor further agrees to provide certification at least annually that the Institutional Review Board has reviewed and approved the procedures, which involve human subjects in accordance with 45 CFR Part 46 and the Assurance of Compliance.

	
 
	
b.
	
The Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under this contract and shall ensure that work is conducted in accordance with the protocol(s) approved by either the IRB or IEC. The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under this contract. The Contractor shall not deem anything in this contract to constitute the Contractor or any subcontractor, agent or employee of the Contractor, or any other person, organization, institution, or group of any kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this contract and will discharge its obligations, duties, and undertakings and the work pursuant thereto, whether requiring professional judgment or otherwise, as an independent Contractor without imputing liability on the part of the Government for the acts of the Contractor or its employees.

	
 
	
c.
	
Contractors involving other agencies or institutions in activities considered to be engaged in research involving human subjects must ensure that such other agencies or institutions obtain their own FWA if they are routinely engaged in research involving human subjects or ensure that such agencies or institutions are covered by the Contractors’ FWA via designation as agents of the institution or via individual investigator agreements (see OHRP website at: http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.pdf).

	
 
	
d.
	
If at any time during the performance of this contract, the Contracting Officer determines, in consultation with OHRP that the Contractor is not in compliance with any of the requirements and/or standards stated in paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. The Contracting Officer may communicate the notice of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may, after consultation with OHRP, terminate this contract in whole or in part, and the Contractor’s 

28

 

	
 
		
name may be removed from the list of those Contractors with approved Human Subject Assurances.

ARTICLE H.2.  CLINICAL RESEARCH

These Clinical Terms apply to all grants and contracts that involve clinical research.

The Government shall have unlimited rights to all protocols, data generated from the execution of these protocols, and final reports, funded by the Government under this contract, as defined in Rights in Data Clause in FAR 52.227-14, Alternate II. The Government reserves the right to request that the Contractor provide any contract deliverable in a non-redacted form, to ensure the Government has the ability to review and distribute the deliverables, as the Government deems necessary.

H.2.1Safety and Monitoring Issues

Institutional Review Board (IRB) or Independent Ethics Committee (IEC) Approval

Before award and then with Annual Progress Reports, the Contractor shall submit to the Government a copy of the current IRB or IEC approved informed consent document, documentation of continuing review and approval and the Office of Human Research Protections (OHRP) FWA number for the institution or site.

If other institutions are involved in the research (e.g., a multicenter clinical trial or study), each institution’s IRB or IEC must review and approve the protocol. They must also provide the Government initial and annual documentation of continuing review and approval, including the current approved informed consent document and FWA number.

The grantee institution must ensure that the applications as well as all protocols are reviewed by their IRB or IEC.

To help ensure the safety of participants enrolled in BARDA-funded studies, the Contractor must provide the Government a summary explanation and copies of documents related to all major changes in the status of ongoing protocols, including the following:

	
 
	
1.
	
All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid.

	
 
	
2.
	
All changes in informed consent documents, identified by version number, date, or both and dates it is valid.

	
 
	
3.
	
Termination or temporary suspension of patient accrual.

	
 
	
4.
	
Termination or temporary suspension of the protocol.

	
 
	
5.
	
Any change in IRB approval.

	
 
	
6.
	
Any other problems or issues that could affect the participants in the studies.

29

 

 

Contractors must notify BARDA through the Contracting Officer’s Representative (COR) and Contracting Officer (CO) of any of the above changes within 24 hours by email, followed by a letter signed by the institutional business official, detailing notification of the change of status to the local IRB and a copy of any responses from the IRB or IEC.

If a clinical protocol has been reviewed by an Institutional Bio-safety Committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.

H.2.2.Data and Safety Monitoring Requirements

The Contractor may be required to conduct independent safety monitoring for clinical trials of investigational drugs, devices, or biologics; clinical trials of licensed products; and clinical research of any type involving more than minimal risk to volunteers. Independent monitoring can take a variety of forms. Phase III clinical trials must have an assigned independent data and safety monitoring board (DSMB); other trials may require DSMB oversight as well. Consistent with other audit provisions in this contract, the Contractor shall inform the Government of any upcoming site visits and/or audits of Contractor facilities funded under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of Contractors and Subcontractors as the Government deems necessary.

The type of monitoring to be used shall be mutually agreed upon between the Contractor and the Government before enrollment starts. Discussions with the responsible COR regarding appropriate safety monitoring and approval of the final monitoring plan by the COR must occur before patient enrollment begins and may include discussions about the appointment of one of the following:

	
 
	
1.
	
Independent Safety Monitor – a physician or other appropriate expert who is independent of the study and available in real time to review and recommend appropriate action regarding adverse events and other safety issues.

	
 
	
2.
	
Independent Monitoring Committee (IMC) or Safety Monitoring Committee (SMC) – a small group of independent investigators and biostatisticians who review data from a particular study.

	
 
	
3.
	
Data and Safety Monitoring Board – an independent committee charged with reviewing safety and trial progress and providing advice with respect to study continuation, modification, and termination. The Contractor may be required to use an established BARDA DSMB or to organize an independent DSMB. All phase III clinical trials must be reviewed by a DSMB; other trials may require DSMB oversight as well. Please refer to: NIAID Principles for Use of a Data and Safety Monitoring Board (DSMB) for Oversight of Clinical Trials Policy. The Government retains the right to place a nonvoting member on the DSMB.

When a monitor or monitoring board is organized, a description of it, its charter or operating procedures (including a proposed meeting schedule and plan for review of adverse events), and 

30

 

 

roster and curriculum vitae from all members must be submitted to and approved by the Government before enrollment starts.

Additionally, the Contractor must submit written blinded summaries of all reviews conducted by the monitoring group to the Government within 30 days of reviews or meetings.

H.2.3.BARDA Protocol Review Process Before Patient Enrollment Begins

BARDA has a responsibility to ensure that mechanisms and procedures are in place to protect the safety of participants in BARDA-supported clinical trials. Therefore, before patient accrual or participant enrollment, the Contractor must provide the following (as applicable) for review and approval by the Government:

	
 
	
4.
	
IRB or IEC approved clinical research protocol identified by version number, date, or both, including details of study design, proposed interventions, patient eligibility, and exclusion criteria;

	
 
	
5.
	
Documentation of IRB or IEC approval, including OHRP FWA number, IRB or IEC registration number, and IRB or IEC name;

	
 
	
6.
	
IRB or IEC approved informed consent document, identified by version number, date, or both and date it is valid;

	
 
	
7.
	
Plans for the management of side effects;

	
 
	
8.
	
Procedures for assessing and reporting adverse events;

	
 
	
9.
	
Plans for data and safety monitoring (see B above) and monitoring of the clinical study site, pharmacy, and laboratory;

	
 
	
10.
	
Documentation that the Contractor and all study staff responsible for the design or conduct of the research have received Good Clinical Practice (GCP) training in the protection of human subjects.

BARDA comments will be forwarded to the Contractor within two weeks (10 business days) of receipt of the above information. The Contractor must address in writing all study design, safety, regulatory, ethical, and conflict of interest concerns raised by the COR to the satisfaction of the Government before patient accrual or participant enrollment can begin. After the Government receives the corrected documentation, a written Contracting Officer Authorization (COA) letter may be provided to the Contractor. This COA provides authorization to the Contractor to execute the specific clinical study funded in part or in whole by the Government.

Documentation of IRB approval, including OHRP FWA number, IRB registration number, and IRB and name, must be provided to the COR within 24 hours of receipt by the Contractor.

31

 

 

H.2.4.Required Time-Sensitive Notification

Under an IND or IDE, the sponsor must provide FDA safety reports of serious adverse events. Under these Clinical Terms of Award, the Contractor must submit copies to the responsible Contracting Officer’s representative (COR) as follows:

	
 
	
1.
	
Expedited safety report of unexpected or life-threatening experience or death – A copy of any report of unexpected or life-threatening experience or death associated with the use of an IND drug, which must be reported to FDA by telephone or fax as soon as possible but no later than seven days after the IND sponsor’s receipt of the information, must be submitted to the CO and the COR within 24 hours of FDA notification.

	
 
	
2.
	
Expedited safety reports of serious and unexpected adverse experiences – A copy of any report of unexpected and serious adverse experience associated with use of an IND drug or any finding from tests in laboratory animals that suggests a significant risk for human subjects, which must be reported in writing to FDA as soon as possible but no later than 15 calendar days after the IND sponsor’s receipt of the information, must be submitted to the Contracting Officer’s Representative within 24 hours of FDA notification.

	
 
	
3.
	
IDE reports of unanticipated adverse device effect – A copy of any reports of unanticipated adverse device effect submitted to FDA must be submitted to the Contracting Officer’s Representative within 24 hours of FDA notification.

	
 
	
4.
	
Expedited safety reports – shall be sent to the COR concurrently with the report to FDA.

	
 
	
5.
	
Other adverse events documented during the course of the trial shall be included in the annual IND or IDE report and reported to the BARDA annually.

In case of problems or issues, the COR will contact the Contractor within 10 working days by email, followed within 7 calendar days by an official letter to the Contractor. The Contractor shall forward the official letter to the principal investigator listing issues and appropriate actions to be discussed.

Safety reporting for research not performed under an IND or IDE.

Ongoing safety reporting requirements for research not performed under an IND or IDE shall be mutually agreed upon by the Contracting Officer’s Representative and the Contractor.

ARTICLE H.3.  HUMAN MATERIALS

The acquisition and supply of all human specimen material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise, will be offered to any person to influence their donation of human material.

32

 

 

ARTICLE H.4.  NEEDLE EXCHANGE

The Contractor shall not use contract funds to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

ARTICLE H.5.  ACKNOWLEDGEMENT OF FEDERAL FUNDING

The Contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money: (1) the percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.

ARTICLE H.6.  RESTRICTIONS ON ABORTIONS

The Contractor shall not use funds for any abortion.

ARTICLE H.7.  GUN CONTROL

The Contractor shall not use contract funds in whole or in part, to advocate or promote gun control.

ARTICLE H.8.  CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

The Contractor shall not use contract funds for (1) the creation of a human embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term “human embryo or embryos” includes any organism, not protected as a human subject under 45 CFR 46 as of the date of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.

Additionally, in accordance with the March 4, 1997 Presidential Memorandum entitled “Prohibition on Federal Funding for Cloning of Human Beings”, federal funds may not be used for cloning of human beings.

ARTICLE H.9.  DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.

ARTICLE H.10.  CARE OF LIVE VERTEBRATE ANIMALS

	
 
	
a.
	
Before undertaking performance of any contract involving animal-related activities where the species is regulated by the United Sates Department of Agriculture (USDA), the 

33

 

 

	
 
		
Contractor shall register with the Secretary of Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CFR 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer.

	
 
	
b.
	
The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR 2.1 through 2.11, or from a source that is exempt from licensing under those sections.

	
 
	
c.
	
The Contractor agrees that the care, use, and intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance (Assurance), the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR subchapter A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.

	
 
	
d.
	
If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor’s name may be removed from the list of those contractors with Animal Welfare Assurances.

Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (Email: ace@aphis.usda.gov ; Web site: (http://www.aphis.usda.gov/wps/portal/aphis/ourfocus/animalwelfare ).

ARTICLE H.11.  ANIMAL WELFARE

All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy).  The PHS Policy can be accessed at: http://grants1.nih.gov/grants/olaw/references/phspol.htm

ARTICLE H.12.  PAPERWORK REDUCTION ACT

	
 
	
a.
	
This contract involves a requirement to collect or record information calling either for answers to identical questions from 10 or more persons other than Federal employees, or information from Federal employees which is outside the scope of their employment, for 

34

 

 

	
 
		
use by the Federal government or disclosure to third parties; therefore, the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.) shall apply to this contract. No plan, questionnaire, interview guide or other similar device for collecting information (whether repetitive or single time) may be used without the Office of Management and Budget (OMB) first providing clearance. Contractors and the Contracting Officer’s Representative shall be guided by the provisions of 5 CFR part 1320, Controlling Paperwork Burdens on the Public, and seek the advice of the HHS operating division or Office of the Secretary Reports Clearance Officer to determine the procedures for acquiring OMB clearance.

	
 
	
b.
	
The Contractor shall not expend any funds or begin any data collection until the Contracting Officer provides the Contractor with written notification authorizing the expenditure of funds and the collection of data. The Contractor shall allow at least 120 days for OMB clearance. The Contracting Officer will consider excessive delays caused by the Government which arise out of causes beyond the control and without the fault or negligence of the Contractor in accordance with the Excusable Delays or Default clause of this contract.

ARTICLE H.13.  RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS

The Contractor shall not use contract funds to maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography.

ARTICLE H.14.  CERTIFICATION OF FILING AND PAYMENT OF TAXES

The Contractor must be in compliance with Section 518 of title V of division H of the Consolidated Appropriations Act of FY 2014.

ARTICLE H.15.  CONFIDENTIALITY OF INFORMATION

	
 
	
a.
	
Confidential information, as used in this article, means information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.

	
 
	
b.
	
The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the “Disputes” clause.

	
 
	
c.
	
If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.

35

 

 

	
 
	
d.
	
Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.

	
 
	
e.
	
Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.

	
 
	
f.
	
Contracting Officer determinations will reflect the result of internal coordination with appropriate program and legal officials.

	
 
	
g.
	
The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.

ARTICLE H.16.  INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR CONFLICTS OF INTERESTS

The Institution (includes any Contractor, public or private, excluding a Federal agency) shall comply with the requirements of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure that Investigators (defined as the project director or principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded under BARDA contracts, or proposed for such funding, which may include, for example, collaborators or consultants) will not be biased by any Investigator financial conflicts of interest. 45 CFR Part 94 is available at the following Web site: http://www.ecfr.gov/cgi- bin/textidx?c=ecfr&SID=0af84ca649a74846f102aaf664da1623&rgn=div5&view=text&node=45:1.0.1.1.51 &idno=45

As required by 45 CFR Part 94, the Institution shall, at a minimum:

	
 
	
a.
	
Maintain an up-to-date, written, enforceable policy on financial conflicts of interest that complies with 45 CFR Part 94, inform each Investigator of the policy, the Investigator’s reporting responsibilities regarding disclosure of significant financial interests, and the applicable regulation, and make such policy available via a publicly accessible Web site, or if none currently exist, available to any requestor within five business days of a request. A significant financial interest means a financial interest consisting of one or more of the following interests of the Investigator (and those of the Investigator’s spouse and dependent children) that reasonably appears to be related to the Investigator’s institutional responsibilities:

	
 
	
1.
	
With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. Included are payments and equity interests;

36

 

 

	
 
	
2.
	
With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator’s spouse or dependent children) holds any equity interest; or

	
 
	
3.
	
Intellectual property rights and interests, upon receipt of income related to such rights and interest.

Significant financial interests do not include the following:

	
 
	
1.
	
Income from seminars, lectures, or teaching, and service on advisory or review panels for government agencies, Institutions of higher education, academic teaching hospitals, medical centers, or research institutes with an Institution of higher learning; and
	
 

	
 
	
2.
	
Income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles.
	
 

	
 
	
b.
	
Require each Investigator to complete training regarding the Institution’s financial conflicts of interest policy prior to engaging in research related to any BARDA funded contract and at least every four years. The Institution must take reasonable steps [see Part 94.4(c)] to ensure that investigators working as collaborators, consultants or subcontractors comply with the regulations.

	
 
	
c.
	
Designate an official(s) to solicit and review disclosures of significant financial interests from each Investigator who is planning to participate in, or is participating in, the BARDA funded research.

	
 
	
d.
	
Require that each Investigator who is planning to participate in the BARDA funded research disclose to the Institution’s designated official(s) the Investigator’s significant financial interest (and those of the Investigator’s spouse and dependent children) no later than the date of submission of the Institution’s proposal for BARDA funded research. Require that each Investigator who is participating in the BARDA funded research to submit an updated disclosure of significant financial interests at least annually, in accordance with the specific time period prescribed by the Institution during the period of the award as well as within thirty days of discovering or acquiring a new significant financial interest.

	
 
	
e.
	
Provide guidelines consistent with the regulations for the designated official(s) to determine whether an Investigator’s significant financial interest is related to BARDA funded research and, if so related, whether the significant financial interest is a financial conflict of interest. An Investigator’s significant financial interest is related to BARDA funded research when the Institution, thorough its designated official(s), reasonably determines that the significant financial interest: Could be affected by the BARDA funded research; or is in an entity whose financial interest could be affected by the research. A financial conflict of interest exists when the Institution, through its designated 

37

 

 

	
 
		
official(s), reasonably determines that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the BARDA funded research.

	
 
	
f.
	
Take such actions as necessary to manage financial conflicts of interest, including any financial conflicts of a subcontractor Investigator. Management of an identified financial conflict of interest requires development and implementation of a management plan and, if necessary, a retrospective review and mitigation report pursuant to Part 94.5(a).

	
 
	
g.
	
Provide initial and ongoing FCOI reports to the Contracting Officer pursuant to Part 94.5(b).

	
 
	
h.
	
Maintain records relating to all Investigator disclosures of financial interests and the Institution’s review of, and response to, such disclosures, and all actions under the Institution’s policy or retrospective review, if applicable, for at least 3 years from the date of final payment or, where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract Records Retention.

	
 
	
i.
	
Establish adequate enforcement mechanisms and provide for employee sanctions or other administrative actions to ensure Investigator compliance as appropriate.

If the failure of an Institution to comply with an Institution’s financial conflicts of interest policy or a financial conflict of interest management plan appears to have biased the design, conduct, or reporting of the BARDA funded research, the Institution must promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will consider the situation and, as necessary, take appropriate action or refer the matter to the Institution for further action, which may include directions to the Institution on how to maintain appropriate objectivity in the BARDA funded research project.

The Contracting Officer and/or HHS may inquire at any time before, during, or after award into any Investigator disclosure of financial interests, and the Institution’s review of, and response to, such disclosure, regardless of whether the disclosure resulted in the Institution’s determination of a financial conflict of interests. The Contracting Officer may require submission of the records or review them on site. On the basis of this review of records or other information that may be available, the Contracting Officer may decide that a particular financial conflict of interest will bias the objectivity of the BARDA funded research to such an extent that further corrective action is needed or that the Institution has not managed the financial conflict of interest in accordance with Part 94.6(b). The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.

If the Contracting Officer determines that BARDA funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an Investigator with a financial conflict of interest that was not managed or reported by the Institution, the Institution shall require the Investigator involved to disclose the financial conflict of interest in each public presentation of the results of the research and to request an addendum to previously published presentations.

38

 

 

ARTICLE H.17.  PUBLICATION AND PUBLICITY

The Contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows:

“This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00001.

Press Releases:

The Contractor shall clearly state, when issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money that: (1) the percentage of the total costs of the program or project which will be financed with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs of the project or program that will be financed by non-Governmental sources.

ARTICLE H.18.  REPORTING MATTERS INVOLVING FRAUD, WASTE, AND ABUSE

Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded programs is encouraged to report such matters to the HHS Inspector General’s Office in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is:

Office of Inspector General

Department of Health and Human Services

TIPS HOTLINE

P.O. Box 23489

Washington, D.C. 20026

ARTICLE H.19.  PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES

The Offeror acknowledges that U.S. Executive Orders and Laws, including but not limited to E.O. 13224 and Pub. L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the Offeror to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.

ARTICLE H.20.  ACCESS TO DOCUMENTATION/DATA

The Government shall have physical and electronic access to all documentation and data generated under this contract, including: all data documenting Contractor performance, all data generated, all communications and correspondence with regulatory agencies and bodies to 

39

 

 

include all audit observations, inspection reports, milestone completion documents, and all Contractor commitments and responses. The Contractor shall provide the Government with an electronic copy of all correspondence with the FDA relating to performance under this contract within 24 hours of receipt. The Government shall acquire unlimited rights to all data funded under any contract awarded in response to this RFP in accordance with FAR Subpart 27.4 and FAR Clause 52.227-14, Alternate II.

ARTICLE H.21.  IDENTIFICATION AND DISPOSITION OF DATA

The Contractor will be required to provide certain data generated under this contract to the Department of Health and Human Services (HHS). HHS reserves the right to review any other data determined by HHS to be relevant to this contract.  The Contractor shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to this contract for the time specified by the FDA.

ARTICLE H.22.  DISSEMINATION OF INFORMATION

No data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order; for submission to any government entity’ for submission to any securities exchange on which the Contractor’s (or its parent corporation’s) securities may be listed for trading or as may otherwise be required to comply with the public company disclosure requirements; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions or contractual obligations, or other business transactions.

ARTICLE H.23.  DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.

ARTICLE H.24.  PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM ASPR FUNDED RESEARCH

All ASPR-funded investigators shall submit to the NIH National Library of Medicine’s (NLM) PubMed Central (PMC) an electronic version of the author’s final manuscript, upon acceptance for publication, of any peer-reviewed scientific publications resulting from research supported in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response. ASPR defines the author’s final manuscript as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. The PMC archive will preserve permanently these manuscripts for use by the public, health care providers, educators, scientists, and ASPR. The Policy directs electronic submissions to the NIH/NLM/PMC: http://www.pubmedcentral.nih.gov .

Additional information is available at http://www.phe.gov/Preparedness/planning/science/Pages/AccessPlan.aspx

40

 

 

ARTICLE H.25.  CONFLICT OF INTEREST

The Contractor represents and warrants that, to the best of the Contractor’s knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, as defined in FAR 2.101 and Subpart 9.5, or that the Contractor has disclosed all such relevant information. Prior to commencement of any work, the Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge and belief, no actual or potential conflict of interest exists or to identify to the Contracting Officer any actual or potential conflict of interest the firm may have. In emergency situations, however, work may begin but notification shall be made within five (5) working days. The Contractor agrees that if an actual or potential organizational conflict of interest is identified during performance, the Contractor shall promptly make a full disclosure in writing to the Contracting Officer. This disclosure shall include a description of actions which the Contractor has taken or proposes to take, after consultation with the Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest. The Contractor shall continue performance until notified by the Contracting Officer of any contrary action to be taken. Remedies include termination of this contract for convenience, in whole or in part, if the Contracting Officer deems such termination necessary to avoid an organizational conflict of interest. If the Contractor was aware of a potential organizational conflict of interest prior to award or discovered an actual or potential conflict after award and did not disclose it or misrepresented relevant information to the Contracting Officer, the Government may terminate the contract for default, debar the Contractor from Government contracting, or pursue such other remedies as may be permitted by law or this contract.

ARTICLE H.26.  IN-PROCESS REVIEW

In Process Reviews (IPR) will be conducted at the discretion of the Government to discuss the progression of the milestones. The Government reserves the right to revise the milestones and budget pending the development of the project. Deliverables may be required when the IPRs are conducted. The Contractor’s success in completing the required tasks under each work segment must be demonstrated through the Deliverables and Milestones specified under SECTION F. Those deliverables will constitute the basis for the Government’s decision, at its sole discretion, to proceed with the work segment, or unilaterally institute changes to the work segment, or terminate the work segment.

IPRs may be scheduled at the discretion of the Government to discuss progression of the contract. The Contractor shall provide a presentation following a prescribed template which will be provided by the Government at least 30 days prior to the IPR. The Contractor shall provide a draft presentation to the Contracting Officer at least 10 days prior to the IPR.

ARTICLE H.27.  PRIVACY ACT APPLICABILITY

	
1.
	
Notification is hereby given that the Contractor and its employees are subject to criminal penalties for violation of the Privacy Act to the same extent as employees of the Government. The Contractor shall assure that each of its employees knows the prescribed rules of conduct and that each is aware that he or she can be subjected to criminal penalty for violation of the Act. A copy of 45 CFR Part 5b, Privacy Act Regulations, may be obtained at http://www.gpoaccess.gov/cfr/index.html

41

 

 

	
2.
	
The Project Officer/COR is hereby designated as the official who is responsible for monitoring Contractor compliance with the Privacy Act.

	
3.
	
The Contractor shall follow the Privacy Act guidance as contained in the Privacy Act System of Records number 09-25-0200. This document may be obtained at the following link: 

http://oma.od.nih.gov/ms/privacy/pa-files/0200.htm

ARTICLE H.28.  SECURITY REPORTING REQUIREMENT

Violations of established security protocols shall be reported to the CO and COR upon discovery within 24 hours of its receipt of any compromise, intrusion, loss or interference of its security processes and procedures. The Contractor shall ensure that all software components that are not required for the operation and maintenance of the database/control system has been removed and/or disabled. The Contractor shall provide to the CO and the COR information appropriate to Information and Information Technology software and service updates and/or workarounds to mitigate all vulnerabilities associated with the data and shall maintain the required level of system security.

The Contractor will investigate violations to determine the cause, extent, loss or compromise of sensitive program information, and corrective actions taken to prevent future violations. The CO in coordination with BARDA will determine the severity of the violation. Any contractual actions resulting from the violation will be determined by the CO.

ARTICLE H.29.  [***]

 

 

42

 

 

PART II – CONTRACT CLAUSES

SECTION I – CONTRACT CLAUSES

FAR 52.252-2  Clauses Incorporated by Reference (Feb 1998)

This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. FAR clauses incorporated into this contract apply to work performed under fixed-price and cost-reimbursement CLINs respectively based on the implementing instructions for each clause.

	
I.1.
	
FEDERAL ACQUISITION REGULATION (FAR) (48 CFR Chapter 1) CLAUSES

Full text of the FAR clauses may be accessed electronically at: 

https://www.acquisition.gov/far/index.html

 

	
Reg
	
Clause
	
Date
	
Clause Title

	
FAR
	
52.202-1
	
Nov 2013
	
Definitions

	
FAR
	
52.203-3
	
Apr 1984
	
Gratuities

	
FAR
	
52.203-5
	
May 2014
	
Covenant Against Contingent Fees

	
FAR
	
52.203-6
	
Sep 2006
	
Restrictions on Subcontractor Sales to the Government

	
FAR
	
52.203-7
	
May 2014
	
Anti-Kickback Procedures

	
FAR
	
52.203-8
	
May 2014
	
Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity

	
FAR
	
52.203-10
	
May 2014
	
Price or Fee Adjustment for Illegal or Improper Activity

	
FAR
	
52.203-12
	
Oct 2010
	
Limitation on Payments to Influence Certain Federal Transactions

	
FAR
	
52.203-13
	
Oct 2015
	
Contractor Code of Business Ethics and Conduct

	
FAR
	
52.203-14
	
Oct 2015
	
Display of Hotline Poster(s)

	
FAR
	
52.203-17
	
Apr 2014
	
Contractor Employee Whistleblower Rights and Requirement To Inform Employees of Whistleblower Rights

	
FAR
	
52.203-19
	
Jan 2017
	
Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements

	
FAR
	
52.204-4
	
May 2011
	
Printed or Copied Double-Sided on Postconsumer Fiber Content Paper

	
FAR
	
52.204-10
	
Oct 2018
	
Reporting Executive Compensation and First-Tier Subcontract Awards

	
FAR
	
52.204-13
	
Oct 2018
	
System for Award Management Maintenance

	
FAR
	
52.209-6
	
Oct 2015
	
Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment

43

 

	
Reg
	
Clause
	
Date
	
Clause Title

	
FAR
	
52.209-9
	
Oct 2018
	
Updates of Publicly Available Information Regarding Responsibility Matters

	
FAR
	
52.209-10
	
Nov 2015
	
Prohibition on Contracting with Inverted Domestic Corporations

	
FAR
	
52.210-1
	
Apr 2011
	
Market Research

	
FAR
	
52.215-2
	
Oct 2010
	
Audit and Records – Negotiation

	
FAR
	
52.215-8
	
Oct 1997
	
Order of Precedence - Uniform Contract Format

	
FAR
	
52.215-11
	
Aug 2011
	
Price Reduction for Defective Certified Cost or Pricing Data—Modifications.

	
FAR
	
52.215-13
	
Oct 2010
	
Subcontractor Certified Cost or Pricing Data—Modifications

	
FAR
	
52.215-15
	
Oct 2010
	
Pension Adjustments and Asset Reversions

	
FAR
	
52.215-18
	
Jul 2005
	
Reversion or Adjustment of Plans for Postretirement Benefits (PRB) other than Pensions

	
FAR
	
52.215-19
	
Oct 1997
	
Notification of Ownership Changes

	
FAR
	
52.215-21
	
Oct 2010
	
Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data -Modifications

	
FAR
	
52.215-23
	
Oct 2009
	
Limitations on Pass-Through Charges

	
FAR
	
52.216-7
	
Aug 2018
	
Allowable Cost and Payment

	
FAR
	
52.216-8
	
Jun 2011
	
Fixed Fee

	
FAR
	
52.219-8
	
Oct 2018
	
Utilization of Small Business Concerns

	
FAR
	
52.219-28
	
July 2013
	
Post-Award Small Business Program Representation

	
FAR
	
52.222-1
	
Feb 1997
	
Notice to the Government of Labor Disputes

	
FAR
	
52.222-2
	
July 1990
	
Payment for Overtime Premiums

	
FAR
	
52.222-3
	
Jun2003
	
Convict Labor

	
FAR
	
52.222-21
	
Apr 2015
	
Prohibition of Segregated Facilities

	
FAR
	
52.222-26
	
Sept 2016
	
Equal Opportunity

	
FAR
	
52.222-29
	
Apr 2015
	
Notification of Visa Denial.

	
FAR
	
52.222-35
	
Oct 2015
	
Equal Opportunity for Veterans

	
FAR
	
52.222-36
	
Jul 2014
	
Equal Opportunity for Workers with Disabilities

	
FAR
	
52.222-37
	
Feb 2016
	
Employment Reports on Veterans

	
FAR
	
52.222-38
	
Feb 2016
	
Compliance with Veterans’ Employment Reporting Requirements

	
FAR
	
52.222-40
	
Dec 2010
	
Notification of Employee Rights Under the National Labor Relations Act

	
FAR
	
52.222-50
	
Jan 2019
	
Combating Trafficking in Persons

44

 

 

	
Reg
	
Clause
	
Date
	
Clause Title

	
FAR
	
52.222-54
	
Oct 2015
	
Employment Eligibility Verification

	
FAR
	
52.223-6
	
May 2001
	
Drug-Free Workplace

	
FAR
	
52.223-18
	
Aug 2011
	
Encouraging Contractor Policies to Ban Text Messaging While Driving

	
FAR
	
52.224-1
	
April 1984
	
Privacy Act Notification

	
FAR
	
52.224-2
	
April 1984
	
Privacy Act

	
FAR
	
52.225-13
	
Jun 2008
	
Restrictions on Certain Foreign Purchases

	
FAR
	
52.227-1
	
Dec 2007
	
Authorization and Consent, Alternate 1 (APR 1984)

	
FAR
	
52.227-2
	
Dec 2007
	
Notice and Assistance Regarding Patent and Copyright Infringement

	
FAR
	
52.227-11
	
May 2014
	
Patent Rights – Ownership by the Contractor

	
FAR
	
52.227-14
	
May 2014
	
Rights in Data – General, Alternate II

	
FAR
	
52.227-16
	
June 1987
	
Additional Data Requirements

	
FAR
	
52.228-7
	
Mar 1996
	
Insurance – Liability to Third Persons

	
FAR
	
52.229-3
	
Feb 2013
	
Federal, State and Local Taxes

	
FAR
	
52.232-1
	
Apr 1984
	
Payments

	
FAR
	
52.232-2
	
Apr 1984
	
Payments under Fixed-Price Research and Development Contracts

	
FAR
	
52.232-8
	
Feb 2002
	
Discounts for Prompt Payment

	
FAR
	
52.232-9
	
Apr 1984
	
Limitation on Withholding of Payments

	
FAR
	
52.232-11
	
Apr 1984
	
Extras

	
FAR
	
52.232-17
	
May 2014
	
Interest

	
FAR
	
52.232-18
	
Apr 1984
	
Availability of Funds

	
FAR
	
52.232-20
	
Apr 1984
	
Limitation of Cost

	
FAR
	
52.232-22
	
Apr 1984
	
Limitation of Funds

	
FAR
	
52.232-23
	
May 2014
	
Assignment of Claims

	
FAR
	
52.232-25
	
Jan 2017
	
Prompt Payment, Alternate I

	
FAR
	
52.232-33
	
Oct 2018
	
Payment by Electronic Funds Transfer--System for Award Management

	
FAR
	
52.232-40
	
Dec 2013
	
Providing Accelerated Payments to Small Business Subcontractors

	
FAR
	
52.233-1
	
May 2014
	
Disputes

	
FAR
	
52.233-3
	
Aug 1996
	
Protest After Award

	
FAR
	
52.233-4
	
Oct 2004
	
Applicable Law for Breach of Contract Claim

45

 

 

	
Reg
	
Clause
	
Date
	
Clause Title

	
FAR
	
52.242-1
	
Apr 1984
	
Notice of Intent to Disallow Costs

	
FAR
	
52.242-3
	
May 2014
	
Penalties for Unallowable Costs

	
FAR
	
52.242-4
	
Jan 1997
	
Certification of Final Indirect Costs

	
FAR
	
52.242-13
	
Jul 1995
	
Bankruptcy

	
FAR
	
52.243-1
	
Aug 1987
	
Changes - Fixed-Price Alternate V (Apr 1984).

	
FAR
	
52.243-2
	
Aug 1987
	
Changes—Cost-Reimbursement Alternate V (Apr 1984).

	
FAR
	
52.243-6
	
Apr 1984
	
Change Order Accounting.

	
FAR
	
52.243-7
	
Jan 2017
	
Notification of Changes

	
FAR
	
52.244-2
	
Oct 2010
	
Subcontracts, Alternate 1 (Jun 2007)

	
FAR
	
52.244-5
	
Dec 1996
	
Competition in Subcontracting

	
FAR
	
52.244-6
	
Jan 2019
	
Subcontracts for Commercial Items

	
FAR
	
52.245-1
	
Jan 2017
	
Government Property

	
FAR
	
52.245-9
	
Apr 2012
	
Use and Charges

	
FAR
	
52.246-23
	
Feb 1997
	
Limitation of Liability.

	
FAR
	
52.246-25
	
Feb 1997
	
Limitation of Liability—Services

	
FAR
	
52.248-1
	
Oct 2010
	
Value Engineering

	
FAR
	
52.249-2
	
Apr 2012
	
Termination for the Convenience of the Government (Fixed-Price)

	
FAR
	
52.249-6
	
May 2004
	
Termination (Cost-Reimbursement)

	
FAR
	
52.249-8
	
Apr 1984
	
Default (Fixed-Price Supply and Service)

	
FAR
	
52.249-9
	
Apr 1984
	
Default (Fixed-Price Research and Development)

	
FAR
	
52.249-14
	
Apr 1984
	
Excusable Delays

	
FAR
	
52.253-1
	
Jan 1991
	
Computer Generated Forms

 

	
I.2.
	
DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR Chapter 3) CLAUSES

Full text of the HHSAR clauses can be found at 
https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html

 

	
HHSAR
	
352.203-70
	
Dec 2015
	
Anti-Lobbying

	
HHSAR
	
352.222-70
	
Dec 2015
	
Offeror Cooperation in Equal Employment Opportunity Investigations

	
HHSAR
	
352.223-70
	
Dec 2015
	
Safety and Health

	
HHSAR
	
352.224-70
	
Dec 2015
	
Privacy Act

	
HHSAR
	
352.233-71
	
Dec 2015
	
Litigation and Claims

	
HHSAR
	
352.270-6
	
Dec 2015
	
Restriction on use of Human Subjects

46

 

 

 

	
I.3.
	
ADDITIONAL CONTRACT CLAUSES

	
I.3.1.
	
Additional HHS Acquisition Regulation (HHSAR) Clauses – In Full Text

352.231-70 Salary rate limitation (Dec 2015)

	
(a)
	
The Contractor shall not use contract funds to pay the direct salary of an individual at a rate in excess of the Federal Executive Schedule Level II in effect on the date the funding was obligated

	
(b)
	
For purposes of the salary rate limitation, the terms ‘‘direct salary,’’ ‘‘salary,’’ and ‘‘institutional base salary’’ have the same meaning and are collectively referred to as ‘‘direct salary’’ in this clause. An individual’s direct salary is the annual compensation that the Contractor pays for an individual’s direct effort (costs) under the contract. Direct salary excludes any income that an individual may be permitted to earn outside of duties to the Contractor. Direct salary also excludes fringe benefits, overhead, and general and administrative expenses (also referred to as indirect costs or facilities and administrative costs).

The salary rate limitation does not restrict the salary that an organization may pay an individual working under a Department of Health and Human Services contract or order; it merely limits the portion of that salary that may be paid with federal funds.

	
(c)
	
The salary rate limitation also applies to individuals under subcontracts.

	
(d)
	
If this is a multiple-year contract or order, it may be subject to unilateral modification by the Contracting Officer to ensure that an individual is not paid at a rate that exceeds the salary rate limitation provision established in the HHS appropriations act used to fund this contract.

	
(e)
	
See the salaries and wages pay tables on the U.S. Office of Personnel Management website for federal Executive Schedule salary levels.

(End of clause)

	
I.3.2.
	
Additional Federal Acquisition Regulation (FAR) (48 CFR Chapter 1) Clauses – In Full Text

52.217-7 Option for Increased Quantity -- Separately Priced Line Item (Mar 1989)

The Government may require the delivery of the numbered line item, identified in the Schedule as an option item, in the quantity and at the price stated in the Schedule. The Contracting Officer may exercise the option by written notice to the Contractor within 30 days. Delivery of added items shall continue at the same rate that like items are called for under the contract, unless the parties otherwise agree.

52.217-8 Option to Extend Services (Nov 1999)

The Government may require continued performance of any services within the limits and at the rates specified in the contract. These rates may be adjusted only as a result of revisions to 

47

 

 

prevailing labor rates provided by the Secretary of Labor. The option provision may be exercised more than once, but the total extension of performance hereunder shall not exceed 6 months. The Contracting Officer may exercise the option by written notice to the Contractor within 30 days.

52.217-9 Option to Extend the Term of the Contract (Mar 2000)

	
(a)
	
The Government may extend the term of this contract by written notice to the Contractor within 30 days; provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least 30 days before the contract expires. The preliminary notice does not commit the Government to an extension.

	
(b)
	
If the Government exercises this option, the extended contract shall be considered to include this option clause.

	
(c)
	
The total duration of this contract, including the exercise of any options under this clause, shall not exceed ten years.

 

 

48

 

 

PART III – ATTACHMENTS

SECTION J– LIST OF ATTACHMENTS

The following documents are attached and incorporated in this contract:

	
 
	
11.
	
Statement of Work, dated December 18, 2019, 12 pages

	
 
	
12.
	
Invoice/Financing Instructions for Cost-Reimbursement Type Contracts

	
 
	
13.
	
Invoice Instructions for Fixed-Priced Type Contracts

	
 
	
14.
	
Sample Invoice Form

	
 
	
15.
	
Report of Government Owned, Contractor Held Property, 1 page

	
 
	
16.
	
Form SF-LLL, Disclosure of Lobbying Activities, 2 pages

	
 
	
17.
	
Paratek Intellectual Property, 20 Pages

	
 
	
18.
	
VMI/SNS Requirements, 3 Pages

 

 

49

 

PART IV – REPRESENTATIONS AND INSTRUCTIONS

SECTION K – REPRESENTATIONS AND CERTIFICATIONS

The following documents are incorporated by reference in this contract:

	
 
	
19.
	
The Contractor’s representations and certifications, including those completed electronically via the System for Award Management (SAM), are incorporated by reference into the contract.

	
 
	
20.
	
Animal Welfare Assurance Numbers (Prime and Subcontractors).

	
 
	
21.
	
Human Subjects Assurance Identification Numbers (Prime and Subcontractors).

The following FAR clause is incorporated by reference:

FAR 52.225-25 – Prohibition on Contracting with Entities Engaging in Certain Activities or Transactions Relating to Iran – Representation and Certifications (Aug 2018)

 

 

50

 

		
	
75A50120C00001
	
Paratek

 

Statement of Work

PREAMBLE

Independently and not as an agency of the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response to the BARDA Request for Proposal (RFP) BARDA CBRN 19-100-SOL-00011.

The Government reserves the right to modify the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&D) contract and the complexities inherent in this and prior programs, at designated milestones the Government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made.

Overall Objectives and Scope

The overall objective of this contract is to procure an antibiotic that can be used under Emergency Use Authorization (EUA) pre-approval or marketing authorization for the treatment and/or post- exposure prophylaxis treatment of pulmonary anthrax. The Contractor will develop NUZYRA® for Animal Rule licensure, with the objective of making it suitable for stockpiling and use to treat infections with B. anthracis. Once suitable regulatory authorization has been achieved or under an applicable stockpiling authority, NUZYRA® will be purchased and delivered to the SNS stockpile or these supplies will become part of a VMI program managed by Paratek. Optional objectives cover activities to help secure the NUZYRA® supply chain, activities to support the commercial sustainability of NUZYRA® with the objective to ensuring continued supply, activities intended to expand the Animal Rule licenses of NUZYRA®, and further purchases for VMI managed by Paratek. The scope of work for this contract includes preclinical, clinical, manufacturing and procurement activities that fall into the following areas: nonclinical activities; clinical activities; manufacturing activities; procurement activities and all associated regulatory, quality assurance, management, and administrative activities. The Research and Development (R&D) efforts and procurement of NUZYRA® will progress in specific stages that cover the base performance (CLINs 1 and 2) segment and seven (7) option segments (CLINs 4 to 10) as specified in this contract. The Contractor must complete specific tasks required in each of the discrete work segments. The scope of work has been broken into the following phases which are discrete work segments:

	
 
	
22.
	
CLIN 1: LATE STAGE DEVELOPMENT TO SUPPORT LICENSURE OF ANTIBIOTIC (ANTHRAX)

	
 
	
23.
	
CLIN 2: INITIAL PURCHASE, STORAGE AND DELIVERY OF ANTIBIOTIC AS FINAL DRUG PRODUCT (FDP)

	
 
	
24.
	
CLIN 3: Not Applicable - NUZYRA IS ALREADY FDA APPROVED FOR COMMUNITY ACQUIRED BACTERIAL PNEUMONIA AND ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS.

	
 
	
25.
	
CLIN 4: SUPPLEMENTAL LATE STAGE DEVELOPMENT FOR ANTHRAX

	
 
	
26.
	
CLIN 5: BARDA SECURITY REQUIREMENTS, [***]

 

 

		
	
75A50120C00001
	
Paratek

 

	
 
	
27.
	
CLIN 6: POST-MARKETING STUDY COMMITMENTS/ REQUIREMENTS FOR COMMERCIAL CABP AND ABSSSI INDICATIONS

	
 
	
28.
	
[***]

	
 
	
29.
	
CLIN 8: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

	
 
	
30.
	
CLIN 9: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

	
 
	
31.
	
CLIN 10: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

	
1.
	
CLIN 1: LATE STAGE DEVELOPMENT TO SUPPORT LICENSURE OF ANTIBIOTIC (ANTHRAX)

The Contractor will continue to develop of NUZYRA® for the treatment of pulmonary Anthrax with the objective of obtaining approval through the FDA Animal Rule.

[***]

	
2.
	
CLIN 2: INITIAL PURCHASE, STORAGE AND DELIVERY OF ANTIBIOTIC AS FINAL DRUG PRODUCT (FDP)

The Contractor will supply 2,500 drug product treatment courses of NUZYRA®

[***]

	
3.
	
CLIN 3: Not Applicable – NUZYRA is already FDA Approved for community acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

	
4.
	
CLIN 4: SUPPLEMENTAL LATE STAGE DEVELOPMENT FOR ANTHRAX

[***]

	
5.
	
CLIN 5: BARDA SECURITY REQUIREMENTS, [***]

[***]

	
6.
	
CLIN 6: POST-MARKETING STUDY COMMITMENTS/ REQUIREMENTS FOR COMMERCIAL CABP AND ABSSSI INDICATIONS

[***]

	
8.
	
CLIN 8: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR/SNS in the manner described in CLIN 2.

 

 

		
	
75A50120C00001
	
Paratek

 

	
9.
	
CLIN 9: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR/SNS in the manner described in CLIN 2.

	
10.
	
CLIN 10: ADDITIONAL PROCUREMENT OF ANTIBIOTIC(S) AS FINAL DRUG PRODUCT (FDP)

The Contractor shall store and maintain under the recommended storage conditions purchased NUZYRA® drug product inventory for the US Government in a VMI or deliver such inventory to the ASPR/SNS in the manner described in CLIN 2.

 

 

 

 

		
	
75A50120C00001
	
Paratek

 

Timeline View of all CLINs provided in this SOW

 

[***]

 

 

		
	
75A50120C00001
	
Paratek

 

	
WBS
	
Milestone
	
Deliverable
	
Success Criteria
	
Go/No-Go
	
Year/Qtr Achieved

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

 

		
	
75A50120C00001
	
Paratek

 

	
WBS
	
Milestone
	
Deliverable
	
Success Criteria
	
Go/No-Go
	
Year/Qtr Achieved

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

 

 

 

		
	
75A50120C00001
	
Paratek

 

ATTACHMENT #2

INVOICE/FINANCING REQUEST INSTRUCTIONS - FOR COST-REIMBURSEMENT TYPE CONTRACTS

Format: Payment requests shall be submitted on the Contractor’s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with the payment request.

Number of Copies: Payment requests shall be submitted in the quantity specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

Frequency: Payment requests shall not be submitted more frequently than once every two weeks in accordance with the Allowable Cost and Payment Clause incorporated into this contract. Small business concerns may submit invoices/financing requests more frequently than every two weeks when authorized by the Contracting Officer.

Cost Incurrence Period: Costs incurred must be within the contract performance period or covered by pre-contract cost provisions.

Billing of Costs Incurred: If billed costs include (1) costs of a prior billing period, but not previously billed, or (2) costs incurred during the contract period and claimed after the contract period has expired, the Contractor shall site the amount(s) and month(s) in which it incurred such costs.

Contractor’s Fiscal Year: Payment requests shall be prepared in such a manner that the Government can identify costs claimed with the Contractor’s fiscal year.

Currency: All BARDA contracts are expressed in United States dollars. When the Government pays in a currency other than United States dollars, billings shall be expressed, and payment by the Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized.

Costs Requiring Prior Approval: Costs requiring the Contracting Officer’s approval, including those set forth in an Advance Understanding in the contract, shall be identified and reference the Contracting Officer’s Authorization (COA) Number. In addition, the Contractor shall show any cost set forth in an Advance Understanding as a separate line item on the payment request.

Invoice/Financing Request Identification: Each payment request shall be identified as either:

	
(a)
	
Interim Invoice/Contract Financing Request: These are interim payment requests submitted during the contract performance period.

 

 

		
	
75A50120C00001
	
Paratek

 

	
(b)
	
Completion Invoice: The completion invoice shall be submitted promptly upon completion of the work, but no later than one year from the contract completion date, or within 120 days after settlement of the final indirect cost rates covering the year in which the contract is physically complete (whichever date is later). The Contractor shall submit the completion invoice when all costs have been assigned to the contract and it completes all performance provisions.

	
(c)
	
Final Invoice: A final invoice may be required after the amounts owed have been settled between the Government and the Contractor (e.g., resolution of all suspensions and audit exceptions).

Preparation and Itemization of the Invoice/Financing Request: The Contractor shall furnish the information set forth in the instructions below. The instructions are keyed to the entries on the Sample Invoice/Financing Request.

	
(a)
	
Designated Billing Office Name and Address: Enter the designated billing office name and address, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule.

	
(b)
	
Contractor’s Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number: Show the Contractor’s name and address exactly as they appear in the contract, along with the name, title, phone number, and e-mail address of the person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer, to whom payment is to be sent. Provide the Contractor’s Vendor Identification Number (VIN), and Data Universal Numbering System (DUNS) number or DUNS+4. The DUNS number must identify the Contractor’s name and address exactly as stated on the face page of the contract. When an approved assignment has been made by the Contractor, or a different payee has been designated, provide the same information for the payee as is required for the Contractor (i.e., name, address, point of contact, VIN, and DUNS).

	
(c)
	
Invoice/Financing Request Number: Insert the appropriate serial number of the payment request.

	
(d)
	
Date Invoice/Financing Request Prepared: Insert the date the payment request is prepared.

	
(e)
	
Contract Number and Order Number (if applicable): Insert the contract number and order number (if applicable).

	
(f)
	
Effective Date: Insert the effective date of the contract or if billing under an order, the effective date of the order.

	
(g)
	
Total Estimated Cost of Contract/Order: Insert the total estimated cost of the contract, exclusive of fixed-fee. If billing under an order, insert the total estimated cost of the order, exclusive of fixed- fee. For incrementally funded contracts/orders, enter the amount currently obligated and available for payment.

	
(h)
	
Total Fixed-Fee: Insert the total fixed-fee (where applicable) or the portion of the fixed-fee applicable to a particular invoice as defined in the contract.

 

 

		
	
75A50120C00001
	
Paratek

 

	
(i)
	
Two-Way/Three-Way Match: Identify whether payment is to be made using a two-way or three- way match. To determine required payment method, refer to the Invoice Submission Instructions in Section G of the Contract Schedule.

	
(j)
	
Office of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule.

	
(k)
	
Central Point of Distribution: Insert the Central Point of Distribution, as identified in the Invoice Submission Instructions in Section G of the Contract Schedule.

	
(l)
	
Billing Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred and for which reimbursement is claimed.

	
(m)
	
Amount Billed - Current Period: Insert the amount claimed for the current billing period by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item.

	
(n)
	
Amount Billed - Cumulative: Insert the cumulative amounts claimed by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item.

	
(o)
	
Direct Costs: Insert the major cost elements. For each element, consider the application of the paragraph entitled “Costs Requiring Prior Approval” on page 1 of these instructions.

	
 
	
(1)
	
Direct Labor: Include salaries and wages paid (or accrued) for direct performance of the contract. List individuals by name, title/position, hourly/annual rate, level of effort (actual hours or % of effort), breakdown by task performed by personnel, and amount claimed.

	
 
	
(2)
	
Fringe Benefits: List any fringe benefits applicable to direct labor and billed as a direct cost. Do not include in this category fringe benefits that are included in indirect costs.

	
 
	
(3)
	
Accountable Personal Property: Include any property having a unit acquisition cost of $5,000 or more, with a life expectancy of more than two years, and sensitive property regardless of cost (see the HHS Contractor’s Guide for Control of Government Property)(e.g. personal computers). Note this is not permitted for reimbursement without pre-authorization from the CO.

On a separate sheet of paper attached to the payment request, list each item for which reimbursement is requested. Include reference to the following (as applicable):

-Item number for the specific piece of equipment listed in the Property Schedule, and

 

 

		
	
75A50120C00001
	
Paratek

 

-COA number, if the equipment is not covered by the Property Schedule.

The Contracting Officer may require the Contractor to provide further itemization of property having specific limitations set forth in the contract.

	
 
	
(4)
	
Materials and Supplies: Include all consumable material and supplies regardless of amount. Detailed line-item breakdown (e.g. receipts, quotes, etc.) is required.

	
 
	
(5)
	
Premium Pay: List remuneration in excess of the basic hourly rate.

	
 
	
(6)
	
Consultant Fee: List fees paid to consultants. Identify consultant by name or category as set forth in the contract or COA, as well as the effort (i.e., number of hours, days, etc.) and rate billed.

	
 
	
(7)
	
Travel: Include domestic and foreign travel. Foreign travel is travel outside of Canada, the United States and its territories and possessions. However, for an organization located outside Canada, the United States and its territories and possessions, foreign travel means travel outside that country. Foreign travel must be billed separately from domestic travel.

	
 
	
(8)
	
Subcontract Costs: List subcontractor(s) by name and amount billed. Provide subcontract invoices/receipts as backup documentation. If subcontract is of the cost-reimbursement variety, detailed breakdown will be required. Regardless, include backup documentation (e.g. subcontractor invoices, quotes, etc.).

	
 
	
(9)
	
Other: Include all other direct costs not fitting into an aforementioned category. If over $1,000, list cost elements and dollar amounts separately. If the contract contains restrictions on any cost element, that cost element must be listed separately.

	
(p)
	
Cost of Money (COM): Cite the COM factor and base in effect during the time the cost was incurred and for which reimbursement is claimed, if applicable.

	
(q)
	
Indirect Costs: Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost category.

	
(r)
	
Fixed-Fee: Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be claimed as provided for by the contract.

	
(s)
	
Total Amounts Claimed: Insert the total amounts claimed for the current and cumulative periods.

	
(t)
	
Adjustments: Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals subject to appeal.

	
(u)
	
Grand Totals

 

 

 

		
	
75A50120C00001
	
Paratek

 

	
(v)
	
Certification of Salary Rate Limitation: If required by the contract (see Invoice Submission Instructions in Section G of the Contract Schedule), the Contractor shall include the following certification at the bottom of the payment request:

“I hereby certify that the salaries billed in this payment request are in compliance with the Salary Rate Limitation Provisions in Section H of the contract.”

**Note the Contracting Officer may require the Contractor to submit detailed support for costs claimed on payment requests. Every cost must be determined to be allocable, reasonable, and allowable per FAR Part 31.

 

 

 

 

		
	
75A50120C00001
	
Paratek

 

ATTACHMENT #3

INVOICE/FINANCING REQUEST INSTRUCTIONS FOR FIXED PRICE TYPE CONTRACTS

General The Contractor shall submit vouchers or invoices as prescribed herein.

Format Standard Form l034, Public Voucher for Purchases and Services Other Than Personal, and Standard Form l035, Public Voucher for Purchases and Services Other than Personal--Continuation Sheet, and the payee’s letterhead or self-designed form should be used to submit claims for reimbursement.

Number of Copies: As indicated in the contract.

Frequency Invoices submitted in accordance with the Payment Clause shall be submitted monthly upon delivery of goods or services unless otherwise authorized by the Contracting Officer.

Preparation and Itemization of the Invoice The invoice shall be prepared as follows:

(a)Designated Billing Office and address:

HHS/ASPR/BARDA

330 Independence Ave, Room G640

Washington DC 20201

ATTN: Contracting Officer

(b)Invoice Number

(c)Date of Invoice

(d)Contract number and date

(e)Payee’s name and address. Show the Contractor’s name (as it appears in the contract), correct address, and the title and phone number of the responsible official to whom payment is to be sent. When an approved assignment has been made by the Contractor, or a different payee has been designated, then insert the name and address of the payee instead of the Contractor.

(f)Description of goods or services, quantity, unit price, (where appropriate), and total amount.

(g)Charges for freight or express shipments other than F.O.B. destination. (If shipped by freight or express and charges are more than $25, attach prepaid bill.)

(h)Equipment - If there is a contract clause authorizing the purchase of any item of equipment, the final invoice must contain a statement indicating that no item of equipment was purchased or include a completed form HHS-565, Report of Capitalized Nonexpendable Equipment.

 

 

		
	
75A50120C00001
	
Paratek

 

Currency: Where payments are made in a currency other than United States dollars, billings on the contract shall be expressed, and payment by the United States Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized.

 

 

 

 

		
	
75A50120C00001
	
Paratek

 

ATTACHMENT #4 - SAMPLE INVOICE FORM

Company Name

 

		
	
Designated Billing Office Name and 

Address:

DHHS/OS/ASPR/AMCG

Attn: Contracting Officer

200 C St., S.W.

Washington, D.C. 20201

Contractor’s Address and Contact 

Information:

 

 

 

POC: Name of accountant or COO or 

signatory authority for invoice

Title: 

Phone: 

E-Mail:

TIN:

DUNS #:
	
Invoice/Finance Number:

Date Invoice Prepared:

Contract No. and Title:

Effective Date & Period of Performance:

Total Estimated Cost of Order:

Office of Acquisitions:

Contracting Officer (insert name here)

Office of Acquisitions Management,

 Contracts, and Grants (AMCG)

 

 

Central Point of Distribution:

This invoice represents reimbursable costs for the period from

 

	
 
	
Amount Billed
	
 

	
Expenditure Category
	
Current
	
Cumulative
	
Contract Value

	
Direct Costs:
	
 
	
 
	
 

	
Direct Labor
	
 
	
 
	
 

	
Fringe Benefits       0.00%
	
 
	
 
	
 

	
Total Labor Costs:
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Overhead                           0.00%
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Travel
	
 
	
 
	
 

	
Subcontracts
	
 
	
 
	
 

	
Consultant Fees
	
 
	
 
	
 

	
Materials and Supplies
	
 
	
 
	
 

	
Other
	
 
	
 
	
 

	
Total Direct Costs
	
 
	
 
	
 

	
 
	
 
	
 
	
 

 

 

		
	
75A50120C00001
	
Paratek

 

	
G&A Rate                            0.00%
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Subtotal:
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Fixed Fee                             0.0%
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Total Amount Claimed
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Adjustments
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Grand Total
	
$      -
	
 
	
 

I certify that all payments requested are for appropriate purposes and in accordance with the contract.

 

Name/signature of signatory authority for invoicing

 

 

 

Attachment 5

													
													
	
REPORT OF GOVERNMENT OWNED, CONTRACTOR HELD PROPERTY

	
CONTRACTOR:
	
 
	
CONTRACT NUMBER:

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
ADDRESS:
	
 
	
REPORT DATE:
	
 

	
ADDRESS1:
	
 
	
 
	
 

	
ADDRESS2:
	
 
	
FISCAL YEAR:
	
 

	
CITY:
	
 
	
 
	
 

	
STATE:
	
 
	
 
	
 

	
ZIP:
	
 
	
 
	
 
	
 

	
CLASSIFICATION
	
BEGINNING OF 

PERIOD
	
ADJUSTMENTS
	
END OF PERIOD

	
 
	
#ITEMS
	
VALUE
	
GFP

ADDED
	
CAP

ADDED
	
DELETIONS
	
#ITEMS
	
VALUE

	
LAND >=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
LAND <$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
OTHER REAL 

>=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
OTHER REAL 

<$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
PROPERTY UNDER 

CONST >=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
PROPERTY UNDER 

CONST <$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
PLANT EQUIP 

>=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
PLANT EQUIP 

<$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
SPECIAL TOOLING 

>=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
SPECIAL TOOLING 

<$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
SPECIAL TEST 

EQUIP >=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
SPECIAL TEST 

EQUIP <$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
AGENCY 

PECULIAR >=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
AGENCY 

PECULIAR <$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
MATERIAL >=$25K 

(CUMULATIVE)
	
 
	
 
	
 
	
 
	
 

	
PROPERTY UNDER 

MFR >=$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
PROPERTY UNDER 

MFR <$25K
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
SIGNED BY:

 

 

													
	
SIGNATURE
	
 
	
DATE SIGNED:
	
 

	
NAME PRINTED
	
 
	
Email
	
 

	
TITLE
	
 
	
TELEPHONE
	
 

 

Report of Government Owned, Contractor Held Property (Rev 10/2014)

 

 

 

Attachment 6

Approved by OMB

0348-0046

DISCLOSURE OF LOBBYING ACTIVITIES

Complete this form to disclose lobbying activities pursuant to 31 U.S.C. 1352

(See reverse for public burden disclosure.)

 

					
	
1. Type of Federal Action:

☐    a. contract

b. grant

c. cooperative agreement

d. loan

e. loan guarantee

f. loan insurance
	
2. Status of Federal Action:

☐    a. bid/offer/application

b. initial award

c. post-award
	
3. Report Type:

a. initial filing

b. material change

For Material Change Only:

year ____ quarter ____

date of last report ____

	
4. Name and Address of Reporting Entity:

 

☐  Prime             ☐  Subawardee

Tier ____, if known :

 

Congressional District, if known:4c
	
5. If Reporting Entity in No. 4 is a Subawardee, Enter 

Name and Address of Prime:

 

 

 

Congressional District, if known :

	
6. Federal Department/Agency:
	
7. Federal Program Name/Description:

 

    CFDA Number, if applicable :

	
8. Federal Action Number, if known :
	
9. Award Amount, if known :

$

	
10. a. Name and Address of Lobbying Registrant

         ( if individual, last name, first name, MI ):
	
b. Individuals Performing Services (including address if different from No. 10a )

(last name, first name, MI ):

 

 

 

	
11.Information requested through this form is authorized by title 31 U.S.C. section 1352. This disclosure of lobbying activities is a material representation of fact upon which reliance was placed by the tier above when this transaction was made or entered into. This disclosure is required pursuant to 31 U.S.C. 1352. This information will be available for public inspection. Any person who fails to file the required disclosure shall be subject to a civil penalty of not less than $10,000 and not more than $100,000 for each such failure.
	
Signature:                                                                      

Print Name:                                                                   

Title:                                                                              

Telephone No.:                               Date:                      

 

	
Federal Use Only:
	
Authorized for Local Reproduction Standard Form LLL (Rev. 7-97)

	
 
	
 

 

PRINT

 

 
 
 

 

 

 

INSTRUCTIONS FOR COMPLETION OF SF-LLL, DISCLOSURE OF LOBBYING ACTIVITIES

This disclosure form shall be completed by the reporting entity, whether subawardee or prime Federal recipient, at the initiation or receipt of a covered Federal action, or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The filing of a form is required for each payment or agreement to make payment to any lobbying entity for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with a covered Federal action. Complete all items that apply for both the initial filing and material change report. Refer to the implementing guidance published by the Office of Management and Budget for additional information.

	
 
	
1.
	
Identify the type of covered Federal action for which lobbying activity is and/or has been secured to influence the outcome of a covered Federal action.

	
 
	
2.
	
Identify the status of the covered Federal action.

	
 
	
3.
	
Identify the appropriate classification of this report. If this is a follow-up report caused by a material change to the information previously reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report by this reporting entity for this covered Federal action.

	
 
	
4.
	
Enter the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check the appropriate classification of the reporting entity that designates if it is, or expects to be, a prime or subaward recipient. Identify the tier of the subawardee, e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited to subcontracts, subgrants and contract awards under grants.

	
 
	
5.
	
If the organization filing the report in item 4 checks “Subawardee,” then enter the full name, address, city, State and zip code of the prime Federal recipient. Include Congressional District, if known.

	
 
	
6.
	
Enter the name of the Federal agency making the award or loan commitment. Include at least one organizational level below agency name, if known. For example, Department of Transportation, United States Coast Guard.

	
 
	
7.
	
Enter the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of Federal Domestic Assistance (CFDA) number for grants, cooperative agreements, loans, and loan commitments.

	
 
	
8.
	
Enter the most appropriate Federal identifying number available for the Federal action identified in item 1 (e.g., Request for Proposal (RFP) number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number; the application/proposal control number assigned by the Federal agency). Include prefixes, e.g., “RFP-DE-90-001.”

 

 

	
 
	
9.
	
For a covered Federal action where there has been an award or loan commitment by the Federal agency, enter the Federal amount of the award/loan commitment for the prime entity identified in item 4 or 5.

	
 
	
10.
	
(a) Enter the full name, address, city, State and zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged by the reporting entity identified in item 4 to influence the covered Federal action.

(b) Enter the full names of the individual(s) performing services, and include full address if different from 10 (a). Enter Last Name, First Name, and Middle Initial (MI).

	
 
	
11.
	
The certifying official shall sign and date the form, print his/her name, title, and telephone number.

 

	
	
According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless it displays a valid OMB Control Number. The valid OMB control number for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of information is estimated to average 10 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0046), Washington, DC 20503.

 

 

 

 

	
	
	
Paratek Patent Applications and Issued Patents [***]

Attachment #7

 

[***]

 

 

 

 

ATTACHMENT #8

Contract requirements for DSNS Logistics Support

[***]prtk-ex1036_510.htm

 

Exhibit 10.36

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

			
	

	
PARATEK PHARMACEUTICALS

paratekpharma.com
	
75 Park Plaza

Boston, MA 02116

617.807.6600

617.275.0039 fax

 

 

December 19, 2019

 

Zai Lab (Shanghai Co., Ltd.)

1043 Halei Road, Building 8, Suite 502

Zhangjiang Hi-tech Park, Shanghai, PRC 201203

[***]

 

Cooley LLP

3175 Hanover Street

Palo Alto, CA 94304

[***]

 

 

		
	
Re:
	
Notice of Assignment to Affiliate

 

We refer to the License and Collaboration Agreement (the “Agreement”), dated as of April 21, 2017, by and between Paratek Bermuda Ltd. a corporation organized and existing under the laws of Bermuda (the “Paratek Bermuda”), and Zai Lab (Shanghai) Co., Ltd., an exempted company organized and existing under the laws of P.R. of China (“Zai”, and each, a “Party”).  

Pursuant to Section 16.2 of the Agreement, providing for assignment of the Agreement to either Party’s Affiliate, as defined therein, we are notifying you that, effective as of December 18, 2019, Paratek Bermuda assigned to its parent and sole stockholder, Paratek Pharmaceuticals, Inc. (the “Assignee”), all of its rights, title, duties, obligations, interest and benefits in and to the Agreement and Assignee consented to such assignment.  

All future correspondence, dealings, deliveries and payments in respect to the Agreement should be made to the Assignee whose details are as follows:

Paratek Pharmaceuticals, Inc.

75 Park Plaza, 4th Floor

Boston, MA 02116

 

[***]

 

 

 

			
	

	
PARATEK PHARMACEUTICALS

paratekpharma.com
	
75 Park Plaza

Boston, MA 02116

617.807.6600

617.275.0039 fax

 

 

 

We would appreciate if you could kindly acknowledge receipt of this notice by signing and returning the attached acknowledgement. 

 

 

Signed  /s/ William M. Haskel   .

Paratek Pharmaceuticals, Inc. 

 

 

 

Signed  /s/ William M. Haskel   .

Paratek Bermuda Ltd.

 

December 19, 2019

 

			
	

	
PARATEK PHARMACEUTICALS

paratekpharma.com
	
75 Park Plaza

Boston, MA 02116

617.807.6600

617.275.0039 fax

 

 

Paratek Pharmaceuticals, Inc.

75 Park Plaza, 4th Floor

Boston, MA 02116

[***]

Fax: 617-275-0039

 

 

		
	
Re:
	
Acknowledgement Notice of Assignment

 

 

We acknowledge receipt of the Notice of Assignment from Paratek Bermuda Ltd. (the “Assignor”) and Paratek Pharmaceuticals, Inc. (the “Assignee”) dated December 18, 2019 (the “Notice”) and confirm that following the assignment described in the Notice, the Assignee shall be entitled to all the Assignor’s rights, title, interest and benefits in and to the License and Collaboration Agreement. 

 

Signed /s/ James Yan   .

For and on behalf of Zai Lab (Shanghai) Co., Ltd.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]